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Summary 
Transition metal catalysis provides versatile methods for the preparation of synthetically useful 
compounds.  Some of these transformations can also be realized by enzymatic catalysis at much higher 
activity and selectivity. The research field of artificial metalloenzymes (ArMs) lies at the interface of 
traditional transition metal catalysis, organocatalysis and enzymatic catalysis. In this line of research,   
new-to-nature transition metal complexes are incorporated into suitable protein scaffolds to explore 
the reactivity and selectivity of the resulting constructs, thereby greatly expanding the repertoire of 
enzymatic catalysts. To match the high efficiency and selectivity displayed by enzymatic catalysts, 
ArMs need to be optimized via effective engineering methods such as directed evolution. 
Within the scope of this thesis, complexes of the transition metal elements Ru, Rh, and Ir were 
combined with mutants of human carbonic anhydrase II (hCA II), and streptavidin from Steptomyces 
avidinii, respectively. Specifically, three types of ArMs were developed : i) an artificial metathesase 
based on human carbonic anhydrase II mutants, ii) a dirhodium carbenoid transferase and iii) artificial 
transfer hydrogenase, the latter two based on streptavidin (Sav) mutants as the protein scaffold. 
The first subsection of chapter 1 provides a general introduction on ArMs, including anchoring and 
engineering strategies and presents their synthetic applications. A particular focus is set on the 
achievements of ArMs in the past two years. The further subsections of chapter 1 detail important 
background information for the constructs under investigation. 
Chapter 2 describes the incorporation of arylsulfonamide anchored Hoveyda-Grubbs Ru-catalysts into 
human carbonic anhydrase II to create an ArM for ring-closing metathesis. The binding affinity of a 
novel Ru-cofactor for hCA II scaffold was determined. The catalytic activity of the ArMs was 
evaluated with different olefin substrates under optimized conditions. The best ArM/substrate pair was 
employed in test reactions under pH-neutral conditions at a low catalyst concentration (10 M). Such 
studies are an important prerequisite for the application of ArMs in vivo. 
In chapter 3, the development of a dirhodium based artificial carbenoid transferase for intermolecular 
cyclopropanation and C-H insertion reactions is outlined. ArMs which combine either bidentate or 
monodentate dirhodium carboxylate complexes with streptavidin were compared in terms of their 
carbene transfer activity. Docking simulations of the biotinylated dirhodium catalysts within 
streptavidin predicted the position of the rhodium center in respect to the biotin-binding vestibule. 
Biocompatibility of the dirhodium complex was tested by performing the dirhodium ArM catalyzed 
cyclopropanation reaction in the presence of whole E. coli cells. 
Chapter 4 summarizes a study on the directed evolution of an iridium based artificial transfer 
hydrogenase. The starting point was a computed structure of a chimeric streptavidin scaffold 
containing an inserted loop partially shielding the active site, which was predicted by Rosetta design. 
Site-directed mutagenesis at four residues was performed to build up a mutant library for screening. A 
self-immolative substrate which releases a fluorescent product upon reduction was developed and used 
in the evolution process to increase the screening throughput. Around 1000 clones were screened with 
iv 
 
the hits sequenced. The promising mutants were purified and their performance was investigated for 
imine reduction in vitro. 
  
v 
 
Table of contents 
Acknowledgment ...................................................................................................................................... i 
Summary ................................................................................................................................................. iii 
Table of contents ...................................................................................................................................... v 
Preface .................................................................................................................................................... vii 
Chapter 1 │ Introduction ......................................................................................................................... 1 
1.1   Artificial metalloenzymes ............................................................................................................ 1 
1.2   Human carbonic anhydrase II ...................................................................................................... 6 
1.2.1   Basic knowledge of human carbonic anhydrase II ............................................................... 6 
1.2.2   Human carbonic anhydrase II as a scaffold for the creation of ArMs .................................. 7 
1.2.3   Summary ............................................................................................................................... 9 
1.3   Bioconjugation of dirhodium complex for the creation of ArMs .............................................. 10 
1.3.1   Dirhodium tetracarboxylate complexes ............................................................................. 10 
1.3.2 Introducing dirhodium moieties as biocatalysts for carbene transfer reactions ................. 12 
1.3.3   Summary ............................................................................................................................. 15 
1.4   Directed evolution of ArMs ....................................................................................................... 16 
1.5   Aim of the thesis ........................................................................................................................ 18 
1.6   Reference ................................................................................................................................... 19 
Chapter 2 │ Carbonic anhydrase II as host protein for the creation of a biocompatible artificial 
metathesase .......................................................................................................................................... 25 
2.1   Abstract...................................................................................................................................... 26 
2.2   Introduction ............................................................................................................................... 26 
2.3   Results and discussion ............................................................................................................... 26 
2.4   Conclusion ................................................................................................................................. 30 
2.5   Supporting information ............................................................................................................. 31 
2.6   Some comments on human carbonic anhydrase II ................................................................... 43 
2.7   Reference ................................................................................................................................... 44 
Chapter 3 │ An artificial metalloenzyme for carbenoid transfer based on a biotinylated dirhodium 
anchored within streptavidin ................................................................................................................ 46 
3.1   Abstract...................................................................................................................................... 47 
3.2   Introduction ............................................................................................................................... 47 
3.3   Results and discussion ............................................................................................................... 48 
3.4   Conclusion ................................................................................................................................. 53 
3.5   Supporting information ............................................................................................................. 54 
vi 
 
3.6   Comments on dirhodium complexes ......................................................................................... 85 
3.7   Reference ................................................................................................................................... 86 
Chapter 4 │ Directed Evolution of Artificial Metalloenzymes for Transfer Hydrogenation of a Self-
Immolative Substrate in E. coli’s Periplasm .......................................................................................... 88 
4.1   Abstract...................................................................................................................................... 89 
4.2   Introduction ............................................................................................................................... 89 
4.3   Results and discussion ............................................................................................................... 89 
4.4   Conclusion ................................................................................................................................. 94 
4.5   Supporting information ............................................................................................................. 96 
4.6 References ................................................................................................................................. 111 
Chapter 5 │ Conclusion and outlook ................................................................................................... 113 
  
vii 
 
Preface 
All schemes, figures, tables and compounds of each chapter in this thesis are numbered independently. 
All experimental details, references for individual chapters are collected at the end of each chapter.
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Chapter 1 │ Introduction 
1.1   Artificial metalloenzymes 
Artificial metalloenzymes (ArMs hereafter) incorporate a catalytic metallocofactor into a protein 
scaffold. Such systems have attracted both chemists and biologists for many years.
1
 By identifying 
various metal complexes stable and active in an aqueous environment, chemists are able to introduce 
new-to-nature reactions in a biological setting.
2
 With the help of protein engineering and mutagenesis 
techniques, the homogeneous catalysts’ activity can be efficiently improved using high throughput 
techniques. Thanks to protein design strategies, ArMs’ structures and functions can be effectively 
engineered and readily optimized.
3
 
There are four well established approaches to anchor synthetic catalysts to protein scaffolds: covalent 
linking (using a covalent bond), supramolecular anchoring (main contributions from the Ward group, 
biotin-streptavidin technology as the most commonly employed tool), dative anchoring (direct 
coordination to the metal center) and metal substitution (native metal ion is replaced by a new metal 
ion). (Figure 1) 
 
Figure 1. (A) General structure of an artificial metalloenzyme. An abiotic cofactor is localized within the protein 
scaffold via (a) covalent linking, (b) dative anchoring, (c) supramolecular interaction and (d) metal substitution. 
In recent years, outstanding research papers
4–8
 and reviews
9–15
 about ArMs with novel cofactors and 
protein scaffolds have been reported, mainly focused on catalytic activity, mechanistic studies,  
structure design and engineering. I summarize below the most recent reports on ArMs after the 
publication of the comprehensive review by the Ward group and Lewis group.
1
 
Myoglobin is currently a very popular scaffold to assemble an ArM to catalyze many transformations. 
As it is naturally evolved for binding dioxygen, researchers have explored its catalytic uses by either 
substituting the metal center in the heme or modifying the porphyrin structure.  
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The Hayashi group provided detailed mechanistic study of a manganese porphycene reconstituted 
myoglobin (rMb) for C-H hydroxylation.
16
 At pH 8.5, a high-resolution crystal structure of rMb 
highlighted the stable ligation of His93 to Mn center and no alternative conformation of His64, which 
are critical for the promotion of C-H hydroxylation. A single turnover reaction and EPR spectroscopy 
allowed the characterization of the Mn
V
-oxo species, the first characterized high-valent species in a 
chemically engineered hemoprotein. (Figure 2) 
 
Figure 2. (a) Proposed reaction mechanism of C-H hydroxylation of water soluble substrate sodium 4-
ethylbenzenesulfonate within rMb. (b) Crystal structure of rMb at pH 8.5 with His64, His93 and water molecule 
around MnPc center. 
More recently, the Hartwig group introduced an abiological metal substitution concept for a non-
natural C-H insertion reaction, using Ir(Me)-PIX substituted myoglobin.
17
 (Scheme 1a) Furthermore, 
they also incorporated the iridium porphyrin into P450 enzyme CYP119. This repurposed enzyme 
displayed kinetic parameters comparated to natural enzymes for C-H insertion.
18
 (Scheme 1b) The 
Fasan group reported myoglobin catalyzed carbene-mediated cyclopropanation under aerobic 
conditions with high catalytic efficiency (up to 6970 TON) and stereoselectivity (up to 99% de and 
ee).
19
 They achieved this by substituting the natural heme cofactor with iron-chlorin e6 complex. 
(Scheme 1c) 
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Scheme 1. A metal substitution strategy was used to assemble new efficient and selective ArMs. Ir-reconstituted 
heme within myoglobin (a) and P450 scaffolds (b) catalyze intramolecular C-H insertion. (c) Fe(Cl)-chlorin e6 
incorporated myoglobin catalyzes stereoselective olefin cyclopropanation. 
There are also examples of ArMs as catalysts in non-natural compounds synthesis. Goti and coworkers 
reported a lysozyme-Ru2(OAc)2 complex that catalyzes the aerobic oxidation of hydroxylamines to 
nitrones. The [Ru2(µ-OAc)2-(H2O)2]
3+
 moiety is hypothesized to bind to  two exposed aspartate groups, 
affording different chemoselectivity for the oxidation, compared to Ru2(OAc)4Cl.
20
 (Scheme 2a) The 
Kamer group reported an artifical hydroformylase by combining rhodium and a lipid-binding protein 
scaffold through robust site-specific phosphine bioconjugation. The newly formed ArM displayed 
remarkable activity and selectivity for the hydroformylation of linear aldehydes.
21
 (Scheme 2b) 
 
Scheme 2. (a) The selective diruthenium incorporation in lysozyme affords an ArM that catalyzes the oxidation 
of hydroxylamines. (b) Highly efficient and selective rhodium hydroformylase for the synthesis of linear long-
chain aldehydes. 
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The Roelfes group reported their effort on designing an enantioselective artificial metallo-hydratase 
based on the transcriptional repressor lactococcal multidrug resistance regulator (LmrR).
22
 The non-
canonical amino acid (2, 2’-bipyridin-5yl)alanine (BpyA) residue introduced in the LmrR scaffold 
binds the catalytic Cu
2+
 ion for enantioselective hydration of the C=C bond of enones. (Scheme 3a) 
The agreement between computational- and experimental results highlighted the power of 
computational design for the creation of novel artificial metallohydratases. The same group also 
incorporated a Cu
2+
 ion into other types of Multidrug resistance regulators (MDRs) as protein 
scaffolds. The resulting ArMs catalyzed the enantioselective Friedel-Crafts alkylation with up to 94 % 
ee. (Scheme 3b) The large hydrophobic and promiscuous binding pocket facilitates the ArMs’ 
design.
23
 The Jäschke group reported Cu
2+
 ion bound G-quadruplex DNA-based ArMs for 
enantioselective Michael addition in water.
24
 (Scheme 3c) Cu
2+ 
was covalently anchored to the 
bipyridyl liangds in the G-quadruplex DNA. CD spectra indicated the limited influence of the linker 
length on the quadruplex structure.  
 
Scheme 3. (a) Enantioselective hydration of enones catalyzed by Cu
2+ 
incorporated LmrR mutants. (b) Cu
2+ 
catalyzed vinylogous Friedel-Crafts alkylation using MDR family as the protein scaffolds. (c) G-quadruplex 
DNA-Cu
2+
 complex catalyzed asymmetric Michael addition. 
ArMs also draw inorganic chemists’ interest for structural, spectroscopic and mechanism studies. 
Fujieta and coauthors reported an artificial osmium peroxygenase relying on a metal-substitution 
strategy of the TM1459 cupin superfamily protein as scaffold. The Os ion binds four histidines in the 
active site, resulting in an octahedral coordination geometry and contributing to stabilize the protein’s 
quaternary structure. The reconstituted ArM catalysed the dihydroxylation of alkenes, affording diols 
up to 9100 TON. Site-directed mutagenesis of this osmium peroxygenase resulted in a threefold 
catalytic improvement.
25
 Wang and coworkers reviewed recent progress on improving ArMs’ activity 
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by optimizing electron-transfer process. Strategies to achieve this include: tuning cofactor’s redox 
potential, tailoring the cofactor’s spatial arrangement, introducing a protein redox partner and etc.12  
In summary, ArMs are becoming a hot research topic. ArMs attract organic chemists to develop new 
catalytic reactions, inorganic chemists to resolve new metal-protein structures. ArMs also appeal to 
enzymologists to explore new protein functions, biologists to discovery cascade reactions with natural 
enzymes and computational scientists to model substrate-protein interactions, predict transition state 
and design new types of ArMs. 
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1.2   Human carbonic anhydrase II  
1.2.1   Basic knowledge of human carbonic anhydrase II 
Human carbonic anhydrase II (hCA II) is a monomeric, single-chain metalloenzyme (Figure 3a) that 
catalyzes the reversible hydration of CO2 into bicarbonate (HCO3
-
) and a proton (H
+
) at an extremely 
high rate, with a kcat/Km of 1.5 X 10
8
 M
-1
s
-1
 and a kcat of 1.4 X 10
6
 s
-1
  (eq. 1, Figure 4).
26
 The active site 
of hCA II comprises a catalytic Zn
2+
 ion coordinated to three imidazole groups of histidines (His94, 
His96 and His119) and one OH
-
 ion/water molecule. Hydrogen bonding interactions between the zinc-
bound water and the hydroxyl moiety of Thr199, which is in turn bridged to the carboxylate moiety of 
Glu106, enhance the nucleophilicity of the zinc-bound water molecule, and further orient CO2 
substrate in a favorable location for nucleophilic attack. pKa of the coordinated H2O to Zn
2+
 is lowered 
to ~6.8 (compared with the pKa of bulk H2O ~14), which sufficiently facilitates the Zn
2+
-OH
-
 
formation at physiological pH.
27
 (Scheme 4) 
 
Figure 3. (a) X-ray structure of native hCA II (PDB: 2CBA) with a Zn
2+ 
ion (gray) coordinated to the three 
histidine residues. (b) Close-up-view of the critical residues involved in the substrate or inhibitor binding in the 
active site. 
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Scheme 4. Mechanism of the hCA II-catalyzed CO2 hydration. Nucleophilic attack of the zinc-bound OH
-
 to CO2 
forms the zinc-bound bicarbonate complex A which isomerizes to B. After the exchange with H2O in 
intermediate B, the bicarbonate product is released and H
+
 is transferred from zinc-bound water to regenerate the 
zinc-hydroxide species via His64.   
Aryl sulfonamide-containing compounds are common inhibitors (Kd = 200-1500 nM) for hCA II, in 
which the residues Gln92, Glu106, Phe131 and Thr199 are involved in their tight binding (Figure 3b). 
The deprotonated sulfonamide is coordinated to Zn
2+
 in the active site. The NH group also interacts 
with Thr199 through a hydrogen bonding, which in turn interacts with the carboxylate group of 
Glu106 by another hydrogen bond. One oxygen atom of the SO2NH moiety binds with the backbone 
NH group of Thr199 through H-bond, with another oxygen atom weakly coordinated to Zn
2+
 (Figure 
4a). Variation of the R group leads to different interactions with the hydrophobic surface, significantly 
affecting the inhibitor’s binding affinity: for benzene sulfonamide Kd vary between 200-1500 nM and 
for acetazolamide Kd = 12 nM (Figure 4b and 4c).
28,29
 
 
Figure 4. (a) hCA II inhibition mechanism by sulfonamide inhibitors. (b) Structure of benzenesulfonamide 
bound to hCA II (PDB: 2WEJ), magenta dashed lines represent hydrogen bond. (c) Structure of acetazolamide 
(AZM) bound to hCA II (PDB: 3HS4, the other two surface bound AZM molecules are not shown)
30
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1.2.2   Human carbonic anhydrase II as a scaffold for the creation of ArMs 
Human carbonic anhydrase II has received significant attention to construct ArMs in recent years. Two  
strategies have been pursued: (a) substitution of the native Zn
2+
 with other transition metals to 
reconstitute the whole scaffold; (b) incorporation of transition metal catalysts bearing arylsulfonamide 
achors to install new catalytic activities. 
Soumillion and coworkers reported the first Mn-substituted carbonic anhydrase for enantioselective 
epoxidation of olefins.
31
 Although the reconstituted Mn-CA displayed lower affinity (micromolar 
range) for the manganese ion, it achieved up to 57% yield and 52% ee for asymmetric epoxidation of 
styrene, higher than the free manganese (Scheme 5a, 5b). The Kazlauskas group succeeded in 
replacing the active-site Zn
2+
 cofactor in carbonic anhydrase with [Rh(cod)2]BF4 and [Rh(acac)(CO)2] 
to achieve the stereoselective hydrogenation of stilbene
32
 and the regioselective hydroformylation of 
styrene
33
, respectively  (Scheme 6c, 6d). To minimize the non-specific binding of Rh(I) to the CA 
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surface, the authors removed the surface histidine residues by chemical modification and site-directed 
mutagenesis. Side products (isomerized trans-stilbene and branched aldehyde) were produced by the 
rhodium located outside of the active site. Lee and coworkers developed the first iridium substituted 
carbonic anhydrase for water oxidation under mild and neutral conditions.
34
 The newly formed Ir-
carbonic anhydrase complex displayed comparable oxygen-evolving activity to traditional Ir-based 
small molecule catalysts. The Hartwig group reported the preparation and characterization of rhodium 
and iridium-substituted carbonic anhydrase.
35
 (Scheme 5e) Advanced characterization methods were 
used in the binding studies, such as colorimetric assay (to quantify the metal occupancy at the native 
metal-binding site), 
15
N-
1
H NMR spectroscopy (to establish the amino acids to which the metal is 
bound), UV-vis spectroscopy (to detect the species during the substitution reaction) and etc. 
 
Scheme 5. (a) Mn-CA catalyzes the enantioselective styrene epoxidation. (b) Surface-exposed histidines (His3, 
His4, His10, His15, His17 are highlighted in cyan, PDB: 1G1D) were pretreated with diethyl pyrocarbonate to 
minimize metal-binding to surface histidines. (c) Rh(I)-CA II catalyzed hydrogenation. (d) Rh(I)-hCA II 
catalyzed hydroformylation. (e) Standard method used to remove the native Zn
2+
 ion from carbonic anhydrase by 
novel metals. 
The Ward group first developed an artificial transfer hydrogenase by incorporating arylsulfonamide-
bearing iridium complexes [η5-Cp*Ir(pico)Cl] with hCA II scaffold (Scheme 6a). After both chemical 
and genetic optimization, complex 6 proved to be the best and achieved up to 82% conversion and 70% 
ee for the transfer hydrogenation of salsolidine precursor (Scheme 6a).
36
 Based on the crystal structure 
of complex 6 · hCA II WT and Rosetta design protein engineering, eight positions in the active site 
were selected for further genetic optimization (Scheme 6b). The newly designed mutants displayed 
significant improvement for binding affinity (46-64 fold), activity (TON from 9 to 98) and 
enantioselectivity (ee from 70% to 96%).
37
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Scheme 6. (a) Ir complex 6 · hCA II catalyzes transfer hydrogenation of the salsolidine precursor and Kd values 
for the new designed mutants. (b) X-ray crystal structure of Ir complex 6 · hCA II WT (PDB: 3ZP9) resulting 
from the Rosetta Design; the mutations suggested by the computational design are highlighted in cyan.
37
 
 
1.2.3   Summary  
Human carbonic anhydrase has been thoroughly investigated concerning its thermostability
38
, protein-
ligand binding, inhibitor development
39
, therapeutic applications
40,41
 and etc. However, it has not been 
widely studied as a protein scaffold to construct ArMs for new-to-nature reactions. In the course of 
this thesis, I have contributed to develop a biocompatible artificial metathesase using hCA II as host 
protein (see chapter 2).  
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1.3   Bioconjugation of dirhodium complex for the creation of ArMs 
1.3.1   Dirhodium tetracarboxylate complexes  
Dirhodium (II) tetracarboxylate complexes have proven to be stable, robust and highly active catalysts 
for carbenoid transfer reactions, such as cyclopropanation, X-H insertion (X=C, N, O, S, Si)
42
, 
arylation of boronic acids
43
, dearomatization of isoquinolinium
44
 and so on. They are also used as 
building blocks for self-assembly
45
 and immobilization on solid support
46
 for heterogeneous catalysis. 
Dirhodium (II) acetate is the simplest dirhodium complex (Scheme 7a). The rhodium atom has 16 
electrons with an open coordination site to accept two electrons from a carbene source (such as diazo 
compounds) via axial coordination, resulting in an eighteen electron complex 7. After the irreversible 
extrusion of N2 from intermediate 7, Rh(II) carbenoid 8 is formed (Scheme 7b). This carbenoid 
forming step is considered to be the rate-limiting step in the catalytic cycle.
47
 The Fürstner group has 
reported the X-ray crystal structure of donor/acceptor donor/donor dirhodium carbene in the solid 
state.
48
 Starting from 8, various synthetically useful transformations have been achieved. In aqueous 
media, the homocoupling of the diazo compound and the O-H insertion environment need to be 
minimized (Scheme 7b). 
 
Scheme 7. (a) Structure of dirhodium acetate. (b) Proposed mechanism of Rh(II) carbenoid formation and 
various carbene transfer reactions. 
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In recent years, highly efficient dirhodium catalysts have been developed by replacing the acetate 
ligands with other bulky carboxylate ligands for asymmetric synthesis, generating excellent diastereo 
and enantioselectivity. The Davies group has contributed most on developing novel chiral dirhodium 
catalysts for cyclopropanation and C-H functionalization. These include Rh2(S-DOSP)4, Rh2(S-
PTAD)4 and so on (Scheme 8a).
49
 Very recently, they reported on even more bulky dirhodium 
catalysts for site and stereo selective insertion of unactivated C-H bonds. Secondary and tertiary C-H 
bonds were selectively functionalized by catalysts control.
50,51
 (Scheme 8b) 
 
Scheme 8. (a) Examples of widely used chiral dirhodium tetracarboxylate catalysts. (b) Site-selective and 
catalyst-controlled C-H functionalization. 
 
Scheme 9. Proposed mechanisms of the dirhodium catalyzed cyclopropanation and C-H insertion. 
The mechanism of dirhodium catalyzed cyclopropanation and C-H insertion are presented in scheme 9. 
The rhodium carbenoid formation is always rate determining. In the cyclopropanation cycle, forming a 
12 
 
cyclopropane ring from an electrophilic carbene and a nucleophilic olefin is generally thought to occur 
in a nonsynchronous manner. The carbene initially reacts with more electron-rich olefinic carbon.
52
 
Also in the C-H insertion cycle, sites that stabilize the positive charge build-up are favored for C-H 
functionalization, forming a three-center, two-electron transition state.
53
 To obtain good 
diastereoselectivity, the highly reactive and electrophilic rhodium carbenoid intermediate needs to be 
stabilized by diazoacetate substrates. Donor/acceptor rhodium cabenoids display enhanced sensitivity 
towards both steric and electronic factors. In general, 2° C-H bonds are most favored for carbene 
insertion because 2° site can best stabilize a positive charge without being too sterically crowded. 
Although 3° C-H bonds are more activated than 2° C-H bonds on an electronic basis, they can only be 
functionalized if they are not too crowded.
54
 
With chiral and bulky tetracarboxylate ligands, the corresponding dirhodium catalysts display 
exceptional enantioselectivity by blocking selected orientations of the incoming substrates. To 
illustrate the versatility of such systems, let’s focus on Rh2(S-DOSP)4, a highly stereoselective and 
versatile catalyst for both cyclopropanation and C-H insertion. (Figure 5a) There are four distinct 
vectors along which a substrate may approach the rhodium carbene moiety. The D2-symmetric 
tetraprolinate DOSP ligands can block two pathways efficiently. The third pathway is blocked by the 
steric bulk of the ester group from the carbene on the back face. This leaves only one vector for the 
alkene substrate to approach the catalyst. (Figure 5b) The bulkier the carboxylate ligands, the higher 
enantioselectivity for the reaction. 
 
Figure 5. (a) Structure of D2-symmetric Rh2(S-DOSP)4 catalyst, the blue disc-like shapes represent tetraprolinate 
ligands in quadrants-separated configurations. (b) Modelled top view of steric factors influencing the facial 
selectivity of the Rh2(S-DOSP)4 stabilized carbene. 
1.3.2 Introducing dirhodium moieties as biocatalysts for carbene transfer 
reactions 
Thanks to their robustness and great activity, dirhodium complexes also draw attention from the 
chemical biology community. Many useful transformations catalyzed by dirhodium catalysts have 
been reported under biological conditions. Ball and coauthors first developed dirhodium 
metallopeptides by anchoring the dirhodium mioety to two glutamate side chains from a peptide.
55
 
These dirhodium metallopeptides catalyze: i) the modification of tryptophan, ii) enantioselective 
carbenoid inertion into Si-H bond
56
 and iii) asymmetric cyclopropanation
57
. (Scheme 10) More 
13 
 
importantly, these catalysts proved to be active in E. coli lysates
58
, paving the way for dirhodium 
catalyzed transformations in E. coli cells. Instead of using traditional dirhodium catalysts with chiral 
carboxylate ligands, the Ball group first introduced biomolecule peptides as the chirality source. The 
Gillingham group reported dirhodium catalyzed alkylation of DNAs and RNAs with good conversions 
and excellent selectivity.
59
 (Scheme 11a) Later, the same group developed various mono- and bis-
substituted dirhodium complexes with different modular carboxylate ligands.
60
 (Scheme 11b) These 
dirhodium complexes catalyzed intramolecular C-H insertion with high efficiency even in aqueous 
environment. Certain dirhodium complexes showed great potential biological applications, such as 
specific localization to DNA in living cells. 
 
Scheme 10. (a) Formation of dirhodium metallopeptide. (b) Dirhodium metallopeptides catalyze carbene 
insertion transformations. 
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Scheme 11. (a) Dirhodium acetate catalyzed alkylation of DNAs and RNAs. (b) Aqueous intramolecular C-H 
insertion catalyzed by newly developed dirhodium complex. 
The Lewis group first created a dirhodium-based ArM by covalently linking the dirhodium core to an 
engineered prolyl oligopeptidase scaffold via strain-promoted azide-alkyne cycloaddition.
61
 The newly 
formed ArM catalyzed the intermolecular cyclopropanation with excellent yield and enantioselectivity. 
(Figure 6a) This is the first example of dirhodium catalyzed asymmetric cyclopropanation using a 
protein scaffold as chiral environment. Later on, the same group achieved the directed evolution of the 
dirhodium ArM cyclopropanase via random mutagenesis.
62
 Error prone PCR and combinatorial codon 
mutagenesis helped to highlight the importance of non-active site mutations for ArM optimization. 
The highly engineered POP scaffold with 12 mutations achieved up to 76 TON and 92% ee for the 
cyclopropanation reaction. (Figure 6b) It also showed improved enantioselectivity for other carbene 
insertion reactions such as Si-H, S-H and N-H insertions. This work highlighted the significant impact 
of distal mutations far away from active site to catalysis, highlighting the importance of random 
mutagenesis for ArM evolution.  
15 
 
 
Figure 6. (a) Initial engineered dirhodium-POP ArM catalyzed asymmetric cyclopropanation. (b) Workflow of 
directed evolution of dirhodium cyclopropanase by random mutagenesis and selected evolution results. 
Mutations are highlighted in different colors: O-ZA4 (grey), 1-NAGS (red), 2-NSIA (orange) and 3-VRVH 
(blue). S301, Y326 and G99 showed great impact on enantioselectivity for cyclopropanation. 
 
1.3.3   Summary  
Dirhodium complexes are efficient and selective catalysts for carbene transfer reactions. Different 
substituted carboxylate ligands result in site selectivity and enantioselectivity. Introducing a dirhodium 
core into biomolecules to form complex biocompatible catalysts for asymmetric catalysis is a rather 
new and promising research area. Unlike the traditional chirality induction by bulky chiral carboxylate 
ligands coordinated to dirhodium moiety, it is difficult to predict how amino acid residues influence 
the dirhodium activity and selectivity even with an X-ray structure. 
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1.4   Directed evolution of ArMs 
Directed evolution is a powerful method to optimize the structure and the function of enzymes. 
Research experts, such as Reetz
63
, Arnold
64
, Turner
65
, Bornscheuer
66
, Liu
67
, Fasan
68
 and etc, have 
reported outstanding work on the directed evolution of natural enzymes. However, it is difficult to 
perform directed evolution for ArMs using the traditional high-throughput screening methods. 
Because the formation of ArMs requires in vitro cofactor incorporation and validated screening assays 
as well as fast analysis methods need to be developed. Only in recent years, a few the directed 
evolution campaigns with ArMs have been reported.
17,62,69–72
 
The Hartwig group achieved a non-natural C-H insertion by replacing the native Fe center of the 
myoglobin scaffold with Ir. Through engineering the apoprotein scaffold, the reconstituted Ir(Me)-
myoglobin ArM showed significant selectivity improvement. (Scheme 12a) Tezcan and coworkers 
modified cytochrome cb562 to self-assemble through hydrophobic interactions into a tetrameric 
complex.
73
 Introduction of a single mutation leads to a remarkable improvement of the hydrolysis 
activity toward p-nitrophenyl acetate and the ampicillin. (Scheme 12b) This hydrolase activity with 
ampicillin directly affected the cell survival on ampicillin-containing media, allowing the authors to 
use cell survival to improve the hydrolysis efficiency by directed evolution.  
 
Scheme 12. (a) Evolutionary trajectory for diversifying and improving enantioselectivity of C-H insertion 
reaction. (b) Progression of evolution for hydrolyzing ampicillin. 
The Ward group reported the directed evolution of artificial metathesase based on the biotin-
streptavidin technology.
74
 The N-terminal OmpA signal sequence allowed to secrete the expressed 
streptavidin into the periplasm, thus enabling the assembly of ArMs in the presence of whole E. coli 
17 
 
cells. This greatly accelerated the screening throughput. The umbelliferone precursor was selected as 
model substrate for the perplasmic screening and lead to the identification of a quintuple mutant 
V47A-N49K-T114Q-A119G-K121R. This mutant was purified and tested in vitro with other 
substrates for ring closing metathesis. Results showed moderate improvement in TON compared with 
WT. 
In the process of the directed evolution of ArMs, some challenging issues still remain, such as 
synthetic cofactor deactivation by cellular components, expression level difference between mutant, 
and effective mutant library construction. There is always no guarantee that the tested reaction activity 
or selectivity could obtain significant improvement, so other techniques such as X-ray structure or 
computational predictions are needed to guide how the directed evolution proceeds. 
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1.5   Aim of the thesis 
The aim of this thesis is to develop two new artificial metalloenzymes which incorporate transition 
metal Ru and Rh into two different protein scaffolds, and to engineer a previously studied artificial 
transfer hydrogenase which incorporates Ir within streptavidin by directed evolution, employing a self-
immolative substrate for high throughput screening. 
Chapter 2 outlines the efforts toward the development of an efficient artificial metathesase employing 
human carbonic anhydrase II as the scaffold. As hCA II has a deep cavity and binds to sulfonamide 
inhibitors with high affinity, various aryl-sulfonamide anchored ruthenium complexes were 
synthesized and tested in combination with hCA II mutants on different diolefin substrates. Ring 
closing metathesis served as the standard reaction to identify the best combinations of substrate, ArM 
and reaction buffer. 
The study described in chapter 3 aims at creating efficient and selective dirhodium bound artificial 
carbenoid transferases based on biotin-streptavidin technology. By site-directed mutagenesis of the 
Sav scaffold, the influence of amino acid residues at specific positions for dirhodium catalyzed 
carbene transfer reactions was explored. As the dirhodium moiety proved to be stable and active in a 
cellular environment, the activity of the best dirhodium ArM was tested employing Sav-expressing E. 
coli cells for future high throughput screening purposes. 
In chapter 4, the feasibility of improved activity based on an inserted loop around the biotin-binding 
vestibule of an artificial transfer hydrogenase is discussed. A streamlined screening platform was set 
up for fast evaluation of the studied constructs.   
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2.1   Abstract 
An artificial metathesase results from incorporation of an Hoveyda-Grubbs catalyst bearing an 
arylsulfonamide anchor within human carbonic anhydrase II. The optimization of the catalytic 
performance is achieved upon combining both chemical and genetic means. Up to 28 TONs were 
obtained within four hours under aerobic physiological conditions. 
2.2   Introduction 
Artificial metalloenzymes result from the incorporation of an abiotic cofactor within a host protein.
1
 
With biomedical applications in mind, it would be desirable to capitalize on a host protein which is 
overexpressed on the surface of cancer cells. Accumulation of the abiotic cofactor, which displays 
high affinity for the latter protein, may allow to site-specifically uncage a drug.
2
 In this context, the 
ring-closing metathesis (RCM) is an attractive reaction as unactivated diolefins can be viewed as 
bioorthogonal. Furthermore, the intramolecular nature of the RCM may facilitate the reaction under 
highly dilute aqueous conditions.
3
 Herein, we report on our efforts to exploit human Carbonic 
Anhydrase II (hCA II hereafter) for the creation of a biocompatible artificial metathesase, Scheme 1. 
Certain forms of cancer overexpress hCA IX, a membrane bound variant of hCA. These 
arylsulfonamide binding proteins are thus privileged targets for cancer therapy.
2,4a
 
 
Scheme 1. Artificial metalloenzyme for ring-closing metathesis. Tethering an arylsulfonamide anchor (green) to 
an Hoveyda-Grubbs type catalyst (black) ensures the localization of the metal moiety within human Carbonic 
Anhydrase II (blue).  
 
2.3   Results and discussion 
Introduction of an arylsulfonamide-anchor on an Hoveyda-Grubbs 2
nd
 generation-type catalyst ensures 
its localization within carbonic anhydrase.
4
 For this purpose, complexes Boc-1, Boc-2 and Boc-3,
5
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were deprotected in situ and reacted with 4-sulfamoylbenzoic acid to afford the corresponding 
sulfonamide-bearing metathesis cofactors 1, 2 and 3, Scheme 2 (see ESI† for full Experimental 
details). 
 
Scheme 2.  Synthesis of olefin metathesase cofactors 1-3 bearing an arylsulfonamide anchor for incorporation 
within hCA II.  
The catalytic performance of the artificial metathesases was evaluated using the ring-closing 
metathesis of N-tosyl diallyl-amine in the presence of 1 mol% ruthenium. To ensure a homogeneous 
mixture, water/DMSO (9/1) was selected. 
Comparison of catalysts 1–3 in the absence of hCA II at pH 6.0 in the presence of 0.1 M MgCl2 
reveals that the bulkiest catalyst 2 outperforms catalysts 1 and 3 (Table 1, entries 1–3). The same trend 
is observed upon incorporation of the cofactors 1–3 into WT hCA II (Table 1, entries 4–6). Catalyst 2 
was thus selected for further optimization. With no MgCl2 added and at pH 7.0, catalyst 2 and the 
corresponding metathesase 2 ⊂ WT hCA II afforded 23 and 14 turnovers after four hours at 37 °C. 
Performing catalysis under strict exclusion of oxygen yielded very similar results. 
Reactions carried out at pH 7.0 and in the presence of 154 mM NaCl (corresponding to physiological 
conditions) yielded 32 and 21 TONs for 2 and 2 ⊂ WT hCA II respectively (Table 1, entries 15 and 
16). As can be appreciated, the TON of the catalyst is pH dependent, both in the presence and in the 
absence of hCA II. The best performance is obtained at lower pH and high salt concentration (Table 1, 
entries 12 and 13). As for other artificial metalloenzymes, we do not believe that the pI of the host 
rotein influences significantly the catalyst performance. 
Compared to the other four artificial metathesases reported to date,
3a–e
 the system presented herein 
presents the following advantageous features (Table 2): (i) it does not require an inert atmosphere; (ii) 
the substrate concentration is the lowest of all systems reported to date; (iii) except for the metathesase 
based on FhuA (which requires SDS, a surfactant), it displays the highest turnover frequency and (iv) 
it catalyzes RCM at pH 7.0, temperature 37 °C and physiological [NaCl] concentrations. These results 
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thus suggest that WT hCA II is a suitable host for the creation of artificial metathesases operating 
under physiological conditions and at low catalyst concentrations (i.e.10 μM).  
 
Table 1  Selected results for the ring-closing metathesis of N-tosyl diallylamine.
a 
 
Entry Catalyst HCA II pH [MClx] mol/L TON
b
 
1 1 − 6.0 MgCl2 0.1 20 ± 0.4 
2 2 − 6.0 MgCl2 0.1 48 ± 0.8 
3 3 − 6.0 MgCl2 0.1 25 ± 0.7 
4 1 WT 6.0 MgCl2 0.1 13 ± 1.3 
5 2 WT 6.0 MgCl2 0.1 45 ± 2.0 
6 3 WT 6.0 MgCl2 0.1 16 ± 1.0 
7 2 WT 6.0 MgCl2 0.1 40 ± 1.5 
8 2 WT 7.0 MgCl2 0.1 28 ± 1.1 
9 2 − 7.0 − 23 ± 2.1 
10 2 WT 7.0 − 14 ± 0.5 
11
c
 2 WT 7.0 − 20 ± 2.3 
12 2 − 5.0 MgCl2 0.5 85 ± 1.0 
13 2 WT 5.0 MgCl2 0.5 78 ± 2.5 
14 2 WT 6.0 − 23 ± 2.6 
15 2 WT 8.0 − 21 ± 1.2 
16 2 − 7.0 NaCl 0.154 32 ± 2.0 
17 2 WT 7.0 NaCl 0.154 21 ± 1.8 
18 2 WT 7.0 NaCl 0.5 32 ± 1.8 
19 2 WT 7.0 NaCl 1.0 29 ± 1.2 
20 2 I91A 7.0 − 18 ± 3.3 
21 2 F131A 7.0 − 16 ± 1.3 
22 2 L198F 7.0 − 18 ± 1.6 
23 2 L198H 7.0 − 22 ± 0.1 
24 2 L198H 7.0 NaCl 0.154 28 ± 0.6 
25 2 L198A 7.0 − 15 ± 1.7 
26 2 L198Q 7.0 − 14 ± 0.1 
27 2 K170A 7.0 − 15 ± 2.0 
a
 Reaction conditions: [substrate] = 1 mM, [catalyst] = 10 μM, [hCA II] = 12 μM, Vtot 200 μL (VDMSO 
20 μL), 37 °C for 4 hours. The reactions were carried out in triplicate. Very similar results were 
obtained under rigorous exclusion of oxygen. 
b
 Turnover number. 
c
 [substrate] = 5 mM, [catalyst] = 50 
μM, [hCA II] = 60 μM. 
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Table 2  Summary of the catalytic performance of artificial metathesases reported to date   
 
To gain insight into the localization of rac-2 within WT hCA II, both enantiomers were docked using 
the GOLD program,
7
 Fig. 1. As can be appreciated, the cofactor fits nicely within the cone-shaped 
binding funnel of hCA II, presenting its alkyl-idene moiety at the surface of the protein (Fig. 1). With 
the aim of improving the TON of the artificial metathesase, residues I91, F131, L198, K170 were 
subjected to site-directed mutagenesis (Table 1, entries 20–27). Lypophylic, polar and potentially 
coordinating aminoacid residues were engineered into these positions. A selection of mutants tested is 
presented in Table 1, entries 20–27. To our delight, 2 ⊂ hCA II L198H yielded significantly improved 
catalytic performance: up to 28 TONs under physiological conditions (Table 1, entry 24). Considering 
that both His198 and Phe198 afford similar TONs, we do not believe that the former residue 
coordinates to ruthenium. At this point however, it is difficult to rationalize or predict the effect a 
point mutations on the outcome of catalysis. 
 
 Hilvert
3b
 Ward
3a 
Schwaneberg
3d, 3e
 Matsuo
3c
 Ward 
[substrate] 
 
5 mM 
 
15.21 mM 
 
100 mM 
 
8 mM 
 
1 mM 
Reaction 
type 
RCM RCM ROMP RCM RCM 
Anchoring 
of Ru-
cofactor 
covalent supramolecular covalent covalent dative 
Host 
protein 
MjHSP
[1]
 
4 mol% 
Avidin 
4.8 mol% 
FhuA DCVFtev[2] 
0.08 mol% 
α-Chymotrypsin 
0.63 mol% 
hCA II 
1 mol% 
Temp. 
Time 
pH 
45 °C 
12 h 
2 
40 °C 
16 h 
4 
25 °C 
68 h 
7 
25 °C 
2 h 
7  
37 °C 
4 h 
7 
Reaction 
conditions 
10 mM HCl,  
Water/t-
BuOH 4/1 
under air 
0.1 M acetate 
Water/DMSO 
5/1 
 0.5 M MgCl2, 
under air 
Water/THF 
9/1 
 SDS 1%  
under N2 
Degassed 
100 mM KCl, 
 under N2 
0.1 M phosphate 
Water/DMSO 
9/1  
under air 
TON 25 20 955 20 28 
[1] MjHSP: M. jannaschii small heat shock protein.  
[2] FhuA DCVFtev: engineered variants of the β-barrel ferric hydroxamate uptake protein component A 
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Figure 1. Docked structure of (R)-2 ⊂ WT hCA II (a) and (S)-2 ⊂ WT hCA II (b). The ruthenium cofactor is 
displayed as stick and hCA II as solvent accessible transparent surface. Residues subjected to mutagenesis are 
highlighted in magenta. 
In order to ensure localisation of the cofactor 2 within hCA II under catalytic conditions, its affinity 
was determined using the dansylamide displacement assay.
8
 Dansylamide (DNSA) displays enhanced 
fluorescence upon incorporation within hCA II. The non-covalent probe can be displaced by high 
affinity arylsulfonamide-bearing hCA II inhibitors, leading to a decrease in fluorescence. 
For DNSA, we obtained a Kd = 4.83 μM and 17.35 μM for WT hCA II and L198H hCA II 
respectively. The displacement assay (see ESI† for details) yielded Kd = 90.40 nM and 205.10 nM for 
2 ⊂ WT hCA II and 2 ⊂ hCA II L198H respectively, Fig. 2. Although we cannot exclude additional 
non-specific binding on the surface of hCA II, we feel that the exquisite specificity of 
arylsulfonamides most probably ensures selective binding to the Zn(His)3 moiety. We tentatively 
attribute the modest quality of the fit to the use of a rac-2 (and thus the presence of two inhibitors with 
potentially different affinities). Under catalytic conditions 96% and 93% of 2 is bound to WT hCA II 
and hCA II L198H respectively. 
 
Figure 2. Determination of the dissociation constant of 2 ⊂ hCA II using the dansylamide displacement assay: 
WT hCA II (a) and L198H hCA II (b) [hCA II] = 0.25 µM,  [Dansylamide] = 20 µM, See SI for full 
experimental details. All measurements were performed in duplicate. 
2.4   Conclusion 
In summary, we have developed an artificial metathesase relying on hCA II as host protein. 
Importantly, the present system operates under aerobic physiological conditions and at low catalyst 
concentrations (i.e.10 μM). Current efforts are directed at evaluating hCA IX, a cell-surface hCA 
variant which is overexpressed in various forms of cancer. 
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2.5   Supporting information 
General aspects 
Materials  and  reagents  were  purchased  from  the  highest  commercially  available  grade  and used 
without further purification. 
1
H and 
13
C spectra were recorded on a Bruker 400 MHz, 500 MHz and 600 MHz Chemical shifts are 
reported in ppm (parts per million). Signals are quoted as s (singlet), d (doublet), t (triplet),  brs (broad)  
and  m (multiplet). Electron Spray Ionization Mass Spectra (ESI-MS) were recorded on a Bruker 
FTMS 4.7T bioAPEX II. Analysis of the catalytic runs was performed on an Agilent 1100 reverse 
phase HPLC. High performance liquid chromatography was performed on Agilent 1100 Series with 
UV-Vis detection.  
hCA II was expressed in 1 L shaking-flasks in an Infors HT Ecotron shaker and  culture growth was 
monitored by UV-Vis at 600 nm with a Varian Cary 50 Scan. The protein was purified via 
sulphonamide affinity chromatography by using AKTA prime (Amersham Pharmacia Biotech, 
Software: PrimeView 5.0). The competitive displacement assays were performed using a Tecan Safire 
spectrophotometer using NUNC 96-well plates. The data were analyzed with Prism 5.0 software. 
Catalyst synthesis 
 
Compound 4, 5, 6, 7, Boc-1 were prepared according to the reported procedures.
9
 
Boc-1 
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A suspension of 
t
BuOK (112 mg, 0.99 mmol) was added to the imidazolinium salt 7 (471 mg, 0.99 
mmol) in dry and degassed THF (15 ml). The mixture was stirred 30 min at room temperature. The 
yellow solution was transferred into a flask containing Hoveyda-Grubbs 1
st
 generation (500 mg, 0.83 
mmol) in benzene (75 ml) and stirred at 80 °C. After 1 hour, CuCl (99 mg, 0.99 mmol) was slowly 
added to the solution and stirred for an additional hour at 80 °C. The solvent was evaporated and 
purification was performed by chromatography (10% EtOAc in cyclohexane) to yield 221 mg (29%) 
of product Boc-1 as a green powder. 
1
H NMR (400 MHz, CD2Cl2): δ 16.33 (s, 1H), 7.49-7.45 (m, 1H), 7.01-6.98 (m, 4H), 6.87-6.80 (m, 
2H), 6.76 (d, J = 8 Hz, 1H), 4.85-4.79 (m, 1H), 4.48-4.41 (m, 1H), 4.18 (t, J = 12 Hz, 1H), 3.86 (dd, J 
= 9.2 Hz, 6.8 Hz, 1H), 3.38-3.25 (m, 2H), 2.34 (s, 14 H), 1.35 (s, 4H), 1.30 (s, 9H), 1.18-1.16 (m, 6 H). 
13
C NMR (100 Hz, CD2Cl2): δ 296.6, 214.5, 156.4, 152.4, 145.5, 139.4, 138.9, 130.5, 130.0, 129.7, 
122.7, 122.6, 113.3, 79.9, 75.6, 64.3, 55.8, 43.2, 32.3, 30.1, 29.8, 28.4, 27.3, 23.1, 21.4, 21.4, 21.2, 
21.2, 21.2, 18.5, 14.3. 
 
Catalyst 1 
 
Boc-1 (45.3 mg, 0.06 mmol, 1 eq.) was dissolved in CH2Cl2 (2 mL). Gaseous HCl (H2SO4 added drop-
wise to NH4Cl) was bubbled through the solution and the mixture was stirred for 2 h at room 
temperature. The deprotection was monitored by thin-layer chromatography (TLC) (cyclohexane/ 
EtOAc 8:1). After consumption of the starting material, the solvent was evaporated under N2 and the 
resulting mixture was dissolved in DMF (1 mL).  
In another flask, 4-sulfamoylbenzoic acid (12.1 mg, 0.06 mmol, 1 eq.) and the coupling agent HCTU 
(27.3 mg, 0.066 mmol, 1.1 eq.) were vigorously stirred in 1 mL of DMF for 20 min. To this latter flask, 
the deprotected complex in DMF was added, followed by Et3N (84.3 L, 0.6 mmol, 10 eq.). The 
resulting mixture was stirred for 20 min at room temperature. The solvent was removed under vacuum. 
Purification by chromatography (50% EtOAc in cyclohexane) yielded 8 mg (16%) of catalyst 1 as a 
green powder. 
1
H NMR (600 MHz, CD2Cl2): δ 16.37 (s, 1H), 7.39-7.88 (m, 4H), 7.58-7.55 (m, 1H), 7.14 (s, 1H), 
7.09 (br, 2H), 6.96 (s, 1H), 6.92-6.91 (m, 2H), 6.87 (d, J = 8.6 Hz, 1H), 4.97-4.94 (m, 3H), 4.67 (br, 
1H), 4.34 (t, J = 11.0 Hz, 1H), 3.95-3.92 (m, 1H), 3.63 (br, 1H), 2.88 (br, 2H), 2.46-2.40 (m, 14H), 
1.43-1.27 (m, 10H). 
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13
C NMR (150 Hz, CD2Cl2): δ 297.2, 211.0, 166.8, 152.5, 145.2, 137.8, 130.7, 130.4, 130.4, 130.0, 
128.6, 126.8, 122.7, 113.3, 75.6, 64.0, 55.7, 55.7, 32.0, 29.9, 21.4, 21.1, 19.1. 
HRMS (ESI, pos.) m/z: [M-Cl]
+
 calcd for C39H46ClN4O4RuS, 803.1971; found: 803.1969. 
 
Compound 8, 9, 10, Boc-2 were  prepared using  the same procedures as  described  for compound 5, 6, 
7, Boc-1. 
 
N
1
, N
2
-bis(2,6-diisopropylphenyl)propane-1,2,3-triamine (8) 
 
Compound 8 (yield 253 mg, 18 %) was prepared from the same procedure of compound 5.
1
 
1
H NMR (400 MHz, CDCl3): δ 7.02-6.88 (m, 6H), 3.38-3.04 (m, 9H), 3.01-2.93 (m, 3H), 2.85 (dd, J = 
12.0 Hz, 5.2 Hz, 1H), 1.17-1.04 (m, 24H). 
13
C NMR (100 Hz, CDCl3): δ 142.7, 142.6, 141.9, 140.4, 124.0, 123.7, 123.6, 123.5, 59.9, 54.3, 53.4, 
44.0, 27.9, 27.7, 24.3, 24.2, 24.1. 
HRMS (ESI, pos.) m/z: [M+H]
+
 calcd for C27H44N3, 410.3536; found: 410.3529. 
 
tert-butyl (2,3-bis((2,6-diisopropylphenyl)amino)propyl)carbamate (9) 
 
Compound 9 (yield 49 mg, 36 %) was prepared from the same procedure of compound 6. 
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1
H NMR (400 MHz, CDCl3): δ 7.03-6.93(m, 6H), 4.96 (br, 1H), 3.45-3.13 (m, 9H), 3.02 (dd, J = 11.7 
Hz, 4.8 Hz, 1H), 2.82 (m, 1H), 1.38-1.36 (m, 10H), 1.18-1.11 (m, 17H), 1.06 (d, J = 6.8 Hz, 6H). 
13
C NMR (100 Hz, CDCl3): δ 156.4, 146.7, 143.3, 142.6, 141.5, 140.9, 123.7, 123.6, 123.5, 123.4, 
85.1, 79.4, 60.2, 53.7, 43.1, 28.4, 27.9, 27.5, 27.4, 26.9, 24.3, 24.1, 24.0. 
HRMS (ESI, pos.) m/z: [M+H]
+
 calcd for C32H52N3O2, 510.4059; found: 510.4054. 
 
tert-butyl ((1,3-bis(2,6-diisopropylphenyl)imidazolidin-4-yl)methyl)carbamate, chloride salt (10) 
 
Compound 10 (yield 212 mg, 89 %) was prepared from the same procedure of compound 7. 
1
H NMR (400 MHz, CDCl3): δ 8.00 (s, 1H), 7.54-7.46 (m, 3H), 7.32-7.26 (m, 3H), 5.45-5.36 (m, 1H), 
5.09 (dd,  J = 12.9 Hz, 9.4 Hz, 1H), 4.62 (t, J = 12.1 Hz, 1H), 3.91-3.84 (m, 1H), 3.46-3.41 (m, 1H), 
3.23-3.13 (m, 1H), 3.09-2.89 (m, 3H), 1.53 (d, J = 6.8 Hz, 3H), 1.48 (d, J = 6.8 Hz, 3H), 1.40 (dd, J = 
6.7 Hz, 0.9 Hz, 6H), 1.36 (s, 9H), 1.26-1.19 (m, 12H).  
13
C NMR (100 Hz, CDCl3): δ 157.6, 156.7, 146.7, 146.6, 146.3, 145.8, 131.6, 129.1, 127.6, 125.6, 
125.2, 125.1, 124.8, 79.2, 65.2, 58.3, 41.4, 29.5, 29.2, 29.1, 29.1, 28.3, 26.0, 25.5, 25.3, 25.2, 23.9, 
23.8, 23.7, 23.2. 
HRMS (ESI, pos.) m/z: [M-Cl]
+
 calcd for C33H50N3O2, 520.3903; found: 520.3893. 
 
Boc-2 
 
Boc-2 was prepared from the same procedure of compound Boc-1. 
A suspension of 
t
BuOK (67.3 mg, 0.6 mmol) was added to the imidazolinium salt 10 (334 mg, 0.6 
mmol) in dry and degassed THF (10 ml). The mixture was stirred 30 min at room temperature. The 
yellow solution was transferred into a flask containing Hoveyda-Grubbs 1
st
 generation (303 mg, 0.50 
mmol) in benzene (40 ml) and stirred at 80 °C. After 1 hour, CuCl (59.4 mg, 0.6 mmol) was slowly 
added to the solution and stirred for an additional hour at 80°C. The solvent was evaporated the crude 
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was purified by flash chromatography (10% EtOAc in cyclohexane) yields 107 mg (21%) of product 
Boc-2 as a green powder. 
1
H NMR (400 MHz, CD2Cl2): δ 16.12 (s, 1H), 7.57-7.53 (m, 1H), 7.44-7.33 (m, 4H), 7.28-7.23 (m, 
2H), 6.80-6.73 (m, 3H), 4.88-4.79 (m, 1H), 4.36-4.19 (m, 3H), 3.53-3.43 (m, 1H), 3.27-3.14 (m, 4H), 
1.39-1.10 (m, 39H),  
13
C NMR (100 Hz, CD2Cl2): δ 288.9, 216.6, 164.8, 156.2, 152.7, 149.6, 144.0, 142.6, 137.4, 130.2, 
130.1, 129.8, 126.0, 125.6, 124.4, 124.2, 123.8, 122.7, 122.6, 113.4, 79.9, 75.6, 66.6, 58.6, 56.6, 48.2, 
43.0, 32.3, 30.1, 29.8, 29.3, 28.6, 28.4, 28.2, 27.2, 26.0, 24.6, 24.1, 23.3, 23.1, 22.1, 21.8, 14.3. 
HRMS (ESI, pos.) m/z: [M-Cl]
+
 calcd for C43H61ClN3O3Ru, 804.3444; found: 804.3430. 
 
Catalyst 2 
 
Catalyst 2 was synthesized according to the preparation procedure used for catalyst 1. Yield: 13.3 mg, 
25%. 
1
H NMR (400 MHz, CD2Cl2): δ 16.1 (s, 1H), 7.90-7.81 (m, 3H), 7.60-7.15 (m, 7H), 6.83-6.57 (m, 4H), 
4.94-4.85 (m, 3H), 4.51-4.33 (m, 2H), 3.79-3.34 (m, 4H), 3.22 (br, 1H), 1.35-0.75 (m, 30H). 
13
C NMR (100 Hz, CD2Cl2): δ 289.3, 217.5, 166.5, 152.9, 145.7, 144.1, 137.6, 130.6, 130.6, 130.3, 
128.7, 127.1, 126.0, 123.0, 122.8, 113.8, 75.9, 41.6, 35.2, 32.5, 32.2, 30.3, 29.6, 27.5, 25.8, 23.2, 22.4, 
21.9, 21.0, 19.1, 14.5, 11.8. 
HRMS (ESI, pos.) m/z: [M-Cl]
+
 calcd for C45H58ClN4O4RuS, 887.2910; found: 887.2915. 
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Compounds 11-17, Boc-3 were synthesized according to literature protocols.
5b
 
Catalyst 3 
 
Catalyst 3 was synthesized according to the preparation procedure of catalyst 1. Yield: 17.4 mg, 21%. 
1
H NMR (500 MHz, CD2Cl2): δ 16.50 (s, 1H), 7.81-7.75 (m, 4H), 7.49-7.46 (m, 2H), 7.24 (s, 2H), 
7.06 (s, 2H), 6.91 (d, J = 7.5 Hz, 1H), 6.76 (d, J = 8.3 Hz, 1H), 5.49 (br, 2H), 4.82-4.75 (m, 1H), 4.62-
4.61 (m, 2H), 4.12-4.07 (m, 4H), 2.43-2.38 (m, 15H), 1.16 (d, J = 6.2 Hz, 6H). 
13
C NMR (145 Hz, CD2Cl2): δ 296.0, 210.9, 166.2, 152.4, 145.5, 145.4, 138.4, 129.7, 122.6, 129.6, 
128.7, 128.4, 128.4, 126.9, 129.9, 122.6, 113.2, 75.7, 52.0, 52.0, 44.0, 21.5, 21.4, 19.8. 
HRMS (ESI, pos.) m/z: [M-Cl]
+
 calcd for C38H44ClN4O4RuS, 789.1815; found: 789.1807. 
 
Binding affinity for the inhibition of hCA II 
A competitive displacement assay was performed according the procedure previously described by 
Zambel.
8a
 
The stock solutions used were phosphate buffer (0.1 M, pH 7.0), dansylamide stock solution (1000 
M, 800 M, 100 M, 10 M) in DMSO, catalyst 2 stock solution (500 M, 50 M, 5 M) in DMSO, 
and hCA II isoform stock (0.278 M ) in phosphate buffer (0.1 M, pH 7.0). 
37 
 
Fluorescence measurements were performed at 29 C by using TECAN and Nunclon black flat-bottom 
96-well plates. The excitation wavelength was set to 280 nm with a fluorescence intensity at 470 nm, 
and the scan speed was set to 100 nm/min. The Kd value for DNSA was determined by titrating 0.25 
M hCA II (180 L) with varying concentrations of DNSA (1~20 L), ranging from 0–40 M in a 
total assay volume of 200 L. The equilibrium dissociation constant for DNSA KDNSA was then 
determined by fitting the data to equation 1 using Prism 5.0 software. 
(Eq. 1) 
The equilibrium dissociation constants for catalyst 2 were determined by competitive binding with 
DNSA. A fixed concentration of  20 M DNSA (5 L) and 0.25 M hCA II (180 L) were then 
titrated against catalyst 2 from 0–30 M (1~15 L). The Kd value of catalyst 2 was then determined by 
fitting the data to equation 2 with Prism 5.0 software. All the titration experiment were performed in 
triplicate. 
(Eq. 2) 
Determination of DNSA and catalyst 2 dissociation constants (Kd) for hCA II WT. 
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Kd (catalyst 2)=90.40 ± 14.89 nM
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Determination of DNSA and catalyst 2 Kd for hCA II mutant L198H. 
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Kd (DNSA)=17.35 ± 1.28 M
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Kd (catalyst 2)=205.10 ± 74.59 nM
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Protein expression and purification 
The plasmid encoding human carbonic anhydrase isozyme II (hCA II) and containing a T7 RNA 
polymerase promoter and an ampicillin resistance gene (pACA) was a generous gift from Carol Fierke, 
Michigan University. The construct of this plasmid has a serine residue at position 2 instead of an 
alanine, with no effect on protein expression or catalytic properties. 
An overnight pre-culture (50 mL) was used to inoculate 1 L of induction media (20 g/L tryptone, 10 
g/L yeast extract, 5 g/L NaCl, 0.36X M9 salts solution, 0.4%glucose, 60 M ZnSO4, 100 g/mL 
Ampicillin and 34 g/mL Chloramphenicol). Cells were grown at 37 C until OD600=0.6-0.8. Protein 
expression were induced through the addition of IPTG (250 M final concentration) and ZnSO4 (450 
M final concentration). After 6 to 7 h of incubation at 37 C at 200 rpm, cells were harvested (4400 
rpm, 15 min at 4 C) and frozen at -20 C overnight. Cells were lysed by activating the gene encoding 
T7 lysozyme by three cycles of “freeze/thraw”. To the cell pellets, a buffer containing Tris-sulfate (50 
mM, pH 8.0), NaCl (50 mM), EDTA (10 mM, pH 8.0), ZnSO4 (0.5 mM), and the protease inhibitors 
PMSF (10 g/mL) was added. Cells were resuspended by vigorously shaking at rt for 1 h, followed by 
adding DNase I (1 g/L final concentration) for another 1 h shaking until complete digestion of 
nucleic acids. The cellular remnants were centrifuged (10,000 rpm, 45 min at 4 C) and cell debris was 
discarded. After identification of hCA II by SDS-PAGE, the crude supernatant was dialyzed in buffer 
(50 mM Tris-sulfate pH 8.0 and 0.5 mM ZnSO4) overnight at 4 C.  
The protein was purified by affinity chromatography. Collected fractions were dialyzed in ddH2O 
overnight. The protein was lyophilized and kept at 4 C as white powder.  
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General procedure for artificial ring closing metathesase of N-tosyldiallylamine 
A stock solution (200 M) of the catalyst was prepared by adding DMSO to an aliquot of the catalyst. 
A stock solution of N-tosyldiallylamine (20 mM) was prepared in a separate vial. A stock solution of 
protein (13.3 M) was prepared by using 0.1 M phosphate buffer pH 7.0. 
In a small glass reaction vial, protein stock solution (180 L) and catalyst DMSO stock solution (10 
L) were added and incubated at 37 °C for 20 min. Then substrate N-tosyldiallylamine stock solution 
(10 μL) was added, and the reaction vial was placed in an incubator for 4 h at 37 °C. 
Upon completion of the reaction, the mixture was added internal standard 2-phenylethanol (100 L, 1 
mM water solution) and MeOH (700 L). The solution mixture was transferred to an eppendorf tube 
and centrifuged at 14’000 rpm for 15 minutes to precipitate the protein. The supernatant (500 μL) was 
transferred in an HPLC vial with additional 500 L water and the sample was subjected to RP-HPLC 
to determine the TON and conversion. 
HPLC analysis. Column: XDB-C18, Eclipse by Agilent: 150 x 4.6 mm; 5 μm with guard column. 
Method: Vinjected: 50 μL. Eluent (Solvent A: H2O) , (Solvent B: CH3CN) 10% B at 0 min, 10% B at 5 
min; 90% B at 20 min; 10 % B at 30 min. Detection at 210 nm. TR 12.2 min (internal standard 2-
phenylethanol), 14.6 min (product 1-tosyl-2,5-dihydro-1H-pyrrole), 16.1 min (substrate N-
tosyldiallylamine). 
 
Docking simulation results 
Both (R) and (S)-enantiomers of catalyst 2 were docked within hCA II WT by GOLD programme. The 
following table summarizes the calculation results of the best fitted catalyst within hCA II. 
Host protein Score* ΔG+ Shbond* Slipo* Hrot* ΔEclash* ΔEint* 
(R)-2  WT 
hCA II 
32.77 -26.92 1.25 187.00 1.80 -8.55 0.84 
(S)-2  WT 
hCA II 
40.86 -33.03 1.29 238.03 1.80 -11.51 1.91 
* Values dimensionless 
+
 Values in kJ·mol
-1
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NMR spectra: 
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2.6   Some comments on human carbonic anhydrase II 
Some comments and suggestions are coming as follows:  
(a) Previous research has highlighted that the histidine imidazoles of the active site are beneficial 
biological ligands by coordination to various transition metals to provide unforeseen biochemical 
activity. Accordingly, metal substitution remains a promising strategy to create new ArMs based on 
hCA II. It is just a question of whether the newly formed metalloprotein is stable, whether the metal-
protein binding affinity is high and whether the second coordination sphere may effectively influence 
the metal’s activity. Also, the coordination of metal ions to the abundant hCA II surface histidine 
residues should be minimized to minimize side reactions. 
(b) New catalytic transition metal catalysts bearing arylsulfonamide anchors need to be synthesized for 
the exploration of new reaction. Here, the catalysts should be active and stable enough under 
physioligical conditions. As multistep synthesis and purification of metal complex (especially the 
ligand screening for the 1
st
 coordination site optimization) are time-consuming, it is advisable to build 
cooperation with organic and organometallic research groups for new reaction development. 
(c) Bioconjugation or ligation with new metal ions to hCA II scaffold is another potential method to 
generate new ArMs. For example, two popular methods are Cu
+
 catalyzed azide-alkyne cycloaddition 
and thiol Michael addition under biorthogonal conditions to cross link biomolecules.
10
  
(d) There are only two reported examples for directed evolution of carbonic anhydrase: one is about 
esterase activity improvement
11
 and the other concerns carbon capture from flue gas
12
. The directed 
evolution of carbonic anhydrase for new transition metal catalysis is still unexplored. Evolving 
carbonic anhydrase in a high throughput manner could be a promising topic in future years.  
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3.1   Abstract 
We report on artificial metalloenzymes that incorporate a biotinylated dirhodium core embedded 
within engineered streptavidin variants. The resulting biohybrid catalyzes the carbenoid insertion in 
C–H bonds and olefins. Chemical- and genetic optimisation allows to modulate the catalytic activity 
of the artificial metalloenzymes that are shown to be active in the perisplasm of E. coli (up to 20 
turnovers). 
 
3.2   Introduction 
Dirhodium(II) tetracarboxylate complexes have been shown to be exceptionally active 
catalysts for carbene transfer reactions including cyclopropanation
1-3 
and X-H insertion (X= C, 
N, O, S, Si etc)
4-8
. Thanks to their robustness, remarkable activity and selectivity under 
physiological conditions, they have also found applications as a versatile tool in chemical 
biology. For this purpose, dirhodium-tetracarboxylate moieties have been linked to 
biomacromolecules including peptides, proteins and oligonucleotides. The Ball group 
developed dirhodium metallopeptides for protein modification and intracellular imaging.
9,10
 
Gillingham and coworkers have reported dirhodium complexes for DNA modification
11
, 
aqueous catalysis and metal uptake within tumor cells
12
. In the context of artificial 
metalloenzymes (ArMs), the Lewis group covalently linked a dirhodium tetracarboxylate 
bearing a terminal alkyne to a genetically-engineered prolyl oligopeptidase equipped with an 
azidophenylalanine. The resulting ArM displayed excellent catalytic properties for 
intermolecular cyclopropanation. Relying on directed evolution (either random or targeted), 
both the activity and the enantioselectivity could be significantly improved.
13,14
 The evolved 
dirhodium cyclopropanase was further shown to catalyze other carbene transfer reactions. 
Pioneered by Wilson and Whitesides in 1978, artificial metalloenzymes based on the biotin-
(strept)avidin technology, have been implemented for a large variety of reactions including: 
(transfer)-hydrogenation
15,16
, cross-coupling
17
, metathesis etc.
18–20
 Since then, many groups 
have reported on the creation of various ArMs relying on alternative anchoring strategies with 
promising catalytic properties.
21–28
 Building upon our experience with ArMs based on the 
biotin-streptavidin technology relying on precious metal cofactors,
29,30
 we present herein our 
efforts to anchor a bulky biotinylated dirhodium moiety within engineered streptavidin to 
catalyze carbenoid transfer reactions, Scheme 1. 
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Scheme 1. Artificial metalloenzymes for carbenoid transfer based on a dirhodium tetracarboxylate 
moiety. The catalytic properties of the ArM can be chemo-genetically optimized: variation of the spacer 
(green) between the biotin anchor and the dicarboxylate moiety can be combined with the introduction 
of point mutations on the streptavidin scaffold (blue stars). 
 
3.3   Results and discussion 
Initially, we designed four bis-chelating dirhodium cofactors 1-4 (Scheme 2). Substitution of 
either two acetate- or trifluoracetate ligands from Rh2(OAc)4 and (cis)-Rh2(OAc)2(OCOCF3)2
31
 
respectively with the m-substituted dicarboxylate-bearing ligands 1b, 2c, 3c, 4b yielded the 
dirhodium intermediates 1c, 2d, 3d, 4c respectively (see ESI for experimental details). 
Biotinylation using biotin derivatives 7a or 7b, through either a hydrazine coupling or an 
esterification afforded the target biotinylated dirhodium cofactors 1-4. In light of the 
remarkable inertness of the Rh2(µ
2−O2CR)4 moiety, we also prepared the dirhodium complexes 
5 and 6. For this purpose, Rh2(OAc)3(OCOCF3)
31
 was treated with biotinylated 
monocarboxylic acid 7c or 7d to afford the corresponding complexes 5 and 6 respectively. All 
biotinylated dirhodium complexes were purified by reversed-phase preparative HPLC and fully 
characterised (See SI). 
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Scheme 2. Biotinylated dirhodium tetracarboxylate complexes tested in this study: (a) catalyst 1 and 4; 
(b) catalyst 2 and 3; (c) catalyst 5 and 6.  Reaction conditions: i) Rh2(OAc)4, N, N-dimethylaniline, 140 
°C, 3 h or (cis)-Rh2(OAc)2(OCOCF3)2, K2CO3, THF, 50 °C, 3 h; ii) (+)-biotin hydrazide 7a, TFA, 
DMSO, rt, 3 h; iii) biotin pentafluoro phenyl ester 7b, NaH, DMSO, rt, 3 h; iv) N, N-
Diisopropylethylamine, DMSO, 50 °C, 2 h. 
 
In the absence of Sav, the dirhodium complexes 1-6 (25 
o
C, pH 7.0, MOPS buffer (0.1 M) 
outperform (i.e. higher turnover number, TON) Rh2(OAc)4 for the cyclopropanation of styrene 
Table 1, entries 1-7). Incorporation of the dirhodium cofactors 1-6 into wild-type streptavidin 
(Sav WT) leads to an erosion in activity (Table 1, entries 9-14). Cofactor 2 outperforms all 
other cofactors: 2 · Sav WT affords 54 TON, compared to 79 TON in the absence of Sav. The 
biotinylated monodentate dirhodium complexes 5 and 6 lead to significantly lower TONs when 
embedded with Sav. We hypothesize that this may be due to the loss of the biotinylated ligand 
accompanied by decomposition of the dirhodium moiety. Increasing or reducing the 
temperature leads to an erosion in TON for 2 · Sav WT (Table 1, entries 15, 16). Screening at 
various pH highlights that the dirhodium cofactor 2 performs best at neutral pH (Table 1, 
entries 17-20). Based on this initial screen, cofactor 2 was selected for all further 
investigations. 
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Table 1  Selected results for the ArMs-catalysed cyclopropanation of styrene with ethyl diazoacetate 8a.
 
 
Entry Catalyst Sav Tem (°C), pH TON
a
 trans/cis 
1 Rh2(OAc)4 − 25, 7.0 2 ± 0 1.5/1 
2 1 − 25, 7.0 68 ± 1 1.4/1 
3 2 − 25, 7.0 79 ± 0 1.3/1 
4 3 − 25, 7.0 79 ± 1 1.4/1 
5 4 − 25, 7.0 52 ± 1 1.3/1 
6 5 − 25, 7.0 60 ± 1 1.4/1 
7 6 − 25, 7.0 46 ± 1 1.4/1 
8 Rh2(OAc)4 WT 25, 7.0 2 ± 0 1.5/1 
9 1 WT 25, 7.0 34 ± 3 1.3/1 
10 2 WT 25, 7.0 54 ± 7 1.4/1 
11 3 WT 25, 7.0 38 ± 2 1.4/1 
12 4 WT 25, 7.0 33 ± 1 1.3/1 
13 5 WT 25, 7.0 3 ± 0 1.1/1 
14 6 WT 25, 7.0 1 ± 0 1.3/1 
15 2 WT 5, 7.0 4 ± 1 1.2/1 
16 2 WT 55, 7.0 0 − 
17 2 WT 25, 4.0
c
 2 ± 0 1.3/1 
18 2 WT 25, 5.0
d
 29 ± 4 1.4/1 
19 2 WT 25, 6.0 50 ± 6 1.4/1 
20 2 WT 25, 8.0 12 ± 4 1.4/1 
a 
Reaction conditions: [styrene] = 10 mM, [8a] = 30 mM,  [catalyst] = 100 µM, [Sav 
biotin binding sites] = 200 µM, Vtot = 400 µL (5% DMSO), 25 °C for 16 hours. 
b
 TON = 
turnover number determined by GC using 1, 3, 5-trimethoxybenzene as internal standard. 
c
 acetate buffer (0.1 M, pH 4.0). 
 d
 acetate buffer (0.1 M, pH 5.0). 
 
For genetic optimization purposes, we screened purified Sav mutants for both 
cyclopropanation and C-H insertion reactions in the presence of cofactor 2. The results are 
summarized in Figure 1a using ethyl diazoacetate 8a and Figure 1b using donor-acceptor ethyl 
diazo(phenyl)acetate 8b respectively. 
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Figure 1. Experimental conditions and selected results for the ArM’s catalysed cyclopropanation of styrene with 
ethyldiazoacetate 8a (a) and diazo(phenyl)acetate 8b (b), and C-H insertion of diazo 10 with 1,4-cyclohexadiene 
(c). 
Next, we investigated the C-H insertion of trifluoroethyl (phenyl)diazoacetate 10 with 1, 4-
cyclohexadiene catalysed by 2 · Sav and mutants thereof. The reaction afforded exclusively the 
allylic insertion product 11, with no double insertion or cyclopropanation byproducts detected. 
A selection of Sav mutants were screened. Gratifyingly, 2 · Sav S112E and K121E 
outperformed both the free cofactor 2 and 2 · Sav WT. No enantioselectivity could be detected 
however.  
To gain structural insight into the localisation of biotinylated dirhodium complex within Sav 
WT, a docking simulation for the hydrated dirhodium complex 2·(H2O)2 within Sav WT was 
performed using the GOLD software suite, Figure 2.
32
 The minimized docked structure 
suggests that the dirhodium moiety protrudes out of the biotin-binding vestibule: The  shortest 
Cα-Rh distances are: 6.1 Å, 6.0 Å, 7.4 Å for the closest lying amino acids S112, K121 and 
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L124 respectively, Figure 2. This may explain why the genetic optimization has such a modest 
effect on the performance of the ArM. 
 
Figure 2. Structure resulting from a docking simulation of dirhodium complex 2·(H2O)2 · Sav WT. The 
protein is displayed as light grey surface and the biotinylated cofactor 2 is displayed as color-coded 
sticks. The closest lying amino acids are displayed as magenta sticks. The closest contacts between the 
cofactor and S112, K121 and L124 are highlighted with yellow dotted lines.  
 
It has been reported that dirhodium tetracarboxylate moieties tolerate cellular components.
33
 
We thus secreted the Sav to the periplasm and screened the artificial cyclopropanase in the 
presence of whole E. coli cells. Figure 3 outlines the protocol implemented for the periplasmic 
screening.
34
 The TOP10(DE3)_pET30 strain was used to express and secrete Sav into the 
periplasm. The following isoforms were tested: Sav WT, S112C, S112D, K121C and K121M. 
After harvesting, the cell pellets were incubated with a MOPS buffer containing 50 µM 
dirhodium cofactor 2 for 30 min on ice. The unbound cofactor 2 was washed away and the 
catalysis buffer containing the substrate was added to the cell pellet. Gratifyingly, the artificial 
cyclopropanase 2 · Sav WT outperformed the free cofactor 2. Introduction of a cysteine 
residue, either at position S112C or K121C leads to improved activities. ICP-MS analysis 
revealed significant Rh-accumulation within E. coli harboring periplasmic Sav (Sav
peri
):  E. 
coli not secreting Sav (empty E. coli) contained 3.2 nmol Rh (corresponding to 6 % uptake 
from the 50 nmol Rh-added to the supernatant). For E. coli harboring Sav
peri
, the Rh-amounts 
determined varied between 5.6 − 8.9 nmol (i.e. 11% − 18% uptake) depending on the mutant. 
Accordingly, the TONs are 10 for the empty E. coli, 9 for Sav
peri
 WT, 17 for Sav
peri
 S112C and 
20 for Sav
peri
 K121C respectively (See SI). 
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Figure 3. An in cellulo artificial cyclopropanase workflow (a), reaction conditions and screening results 
(b) for the periplasmic screening. 
 
3.4   Conclusion 
In summary, we have developed an artificial carbenoid transferase based on the biotin-
streptavidin technology. The resulting ArMs catalyse both intermolecular cyclopropanation 
and C-H insertion. The dirhodium ArMs showed their ability to maintain their activity in the 
periplasm of E. coli cells, highlighting the robustness of the dirhodium moiety in a cellular 
environment. This paves the way for high-throughput screening to further optimize the activity 
and the selectivity of such artificial carbenoid-transferases based on the biotin-streptavidin  
technology. In this context, we have recently reported on chimeric Sav that incorporate 
extended loops around the biotin-binding vestibule.
35
 We hypothesize that these chimeras may 
offer a better-defined environment around the bulky dirhodium cofactor 2, thus offering a 
means to influence the selectivity of the reactions.  
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3.5   Supporting information 
General aspects 
Materials and reagents were purchased from the highest commercially available grade and used 
without further purification. 
1
H and 
13
C spectra were recorded on a Bruker 400 MHz, 500 MHz and 600 MHz. Chemical shifts are 
reported in ppm (parts per million). Signals are quoted as s (singlet), d (doublet), t (triplet), brs (broad) 
and m (multiplet). High resolution 
1
H, 
13
C and 2D spectra (for final biotinylated dirhodium complexes) 
were recorded on a 600 MHz Avance III equipped with a QCI probe-head. Electron-Spray Ionization 
Mass Spectra (ESI-MS) were recorded on a Bruker FTMS 4.7T bioAPEX II. High resolution mass 
spectra (HRMS) were measured on a Bruker maXis 4G QTOF ESI mass spectrometer. Reversed-
phase preparative HPLC was performed on a varian prepstar solvent delivery module equipped with a 
Gemini NX5u RP18e 250*21.1 mm column (Phenomenex) protected by SecurityGuard PREP 
Cartridge (Gemini C18 15 × 21.2 mm). Cyclopropanation catalysis samples were analyzed on an 
Agilent 6890 Series GC System with Agilent CP-Chirasil-Dex CB column (25 m × 0.25 mm × 0.25 
μm).  The results of C-H insertion catalysis were analyzed by Agilent HP-1 column (30 m × 0.32 mm 
× 0.25 μm). High-performance liquid chromatography was performed on Agilent 1100 Series with 
UV-Vis detection.  
 
Catalysts synthesis 
Synthesis of catalyst 1 
 
Compounds 1a, 1b, 1c and 1 were prepared according to reported procedures.
12
 
 
Synthesis of catalyst 2 
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Compound 2a was synthesized according to a reported method.
36
           
1
H NMR (400 MHz, CDCl3) δ 7.07 (t, J = 8.2 Hz, 1H), 6.49 (dd, J = 8.2, 2.3 Hz, 2H), 6.39 (d, J = 2.3 
Hz, 1H), 4.24 (q, J = 7.1 Hz, 4H), 1.56 (s, 12H), 1.25 (t, J = 7.1 Hz, 6H). 
diethyl 2,2'-((5-hydroxy-1,3-phenylene)bis(oxy))bis(2-methylpropanoate) 2b   
 
To a 50 mL two-necked round-bottom flask, compound 2a (0.8957g, 2.65 mmol, 1 equiv.), 
[Ir(COD)(OMe)]2 (17.6 mg, 26.5 µmol, 1 mol%), 4,4'-di-tert-butylbipyridine (14.2 mg, 52.9 µmol, 2 
mol%) and B2pin2 (470.5 mg, 1.85 mmol, 0.7 equiv.) were added. The flask was evacuated and 
charged with N2 three times. Under a mild N2-flow, THF (20 mL) was added and the reaction mixture 
was heated at 80 °C for 48 h. The solvent was removed under reduced pressure, and the resulting 
crude mixture was purified by flash chromatography (EtOAc / cyclohexane = 1 / 5) to yield a crude 
product. This product was dissolved in 40 mL MeOH and an H2O2 solution (30% in water, 3 mL) was 
added. The reaction mixture was stirred at rt for 2 h and the solvent was evaporated. Purification by 
flash chromatography (EtOAc / cyclohexane = 1 / 3) afforded phenol 2b (0.5795 g, 62%) as colorless 
oil. 
1
H NMR (400 MHz, CDCl3) δ 6.03 (d, J = 2.1 Hz, 2H), 5.94 (t, J = 2.1 Hz, 1H), 5.24 (s, 1H), 4.24 (q, 
J = 7.1 Hz, 4H), 1.56 (s, 14H), 1.25 (t, J = 7.1 Hz, 7H). 
13
C NMR (100 Hz, CDCl3) δ 174.5, 157.0, 156.8, 103.0, 100.9, 79.4, 61.7, 25.5, 14.2. 
HRMS (ESI, pos.) m/z: [M + Na]
+
 calcd for C18H26NaO7, 377.1576; found: 377.1576. 
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2,2'-((5-hydroxy-1,3-phenylene)bis(oxy))bis(2-methylpropanoic acid) 2c   
 
Phenol 2b (0.5795 g, 1.64 mmol, 1 equiv.) and LiOH·H2O (0.686 g, 16.4 mmol, 10 equiv.) were 
dissolved in MeOH / H2O = 4 / 1 (20 mL). The mixture was heated at 60 °C for 3 h. After cooling to rt, 
the mixture was acidified with 1 M HCl to pH 1 and extracted with EtOAc (30 mL × 3). The organic 
layer was washed with brine and dried over Na2SO4. Concentration under reduced pressure yielded 
diacid 2c (0.478 g, 98%) as white solid. 
1
H NMR (400 MHz, CD3OD) δ 5.93 (d, J = 2.1 Hz, 2H), 5.85-5.84 (m, 1H), 1.44 (s, 12H). 
13
C NMR (100 Hz, CD3OD) δ 177.7, 159.5, 158.1, 103.2, 102.0, 80.1, 25.8. 
HRMS (ESI, pos.) m/z: [M + Na]
+
 calcd for C14H18NaO7, 321.0950; found: 321.0950. 
 
Dirhodium complex 2d 
 
A round-bottom flask was charged diacid 2c (26.9 mg, 0.09 mmol, 1 equiv.), (cis)-
Rh2(OAc)2(OCOCF3)2 (49.5 mg, 0.09 mmol, 1 equiv.) and K2CO3 (24.9 mg, 0.18 mmol, 2 equiv.). 
THF (10 mL) was added and the mixture was heated to 50 °C for 3 h. The solvent was removed and 
crude mixture was purified by flash chromatography (EtOAc / cyclohexane = 1 / 1). Complex 2d (37.1 
mg, 66%) was isolated as a green solid. 
1
H NMR (400 MHz, CD3OD) δ 5.92 (m, 2H), 5.62-5.61 (m, 1H), 1.44 (s, 12H), 1.81 (s, 6H), 1.33 (m, 
12H). 
13
C NMR (100 Hz, CD3OD) δ 193.6, 192.1, 159.3, 157.9, 103.4, 102.2, 81.4, 68.2, 25.5, 23.0. 
HRMS (ESI, pos.) m/z: [M + Na]
+
 calcd for C18H22NaO11Rh2, 642.9170; found: 642.9175. 
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Catalyst 2 
 
Complex 2d (14.8 mg, 23.8 µmol, 1 equiv.) and NaH (60%, 0.9 mg, 23.8 µmol, 1 equiv.) were added 
into a round-bottom flask. DMSO (0.8 mL) was added and the mixture stirred for 1 h at 50 °C. Biotin-
pentafluorophenyl ester 7b (10.7 mg, 26.2 µmol, 1.1 equiv.) was added and the resulting solution was 
stirred at rt for 3 h. The crude reaction mixture was purified by preparative reversed-phase HPLC to 
afford catalyst 2 (10.3 mg, 51%) as light purple solid. HPLC gradient: MeCN / H2O, 2% to 70% for 40 
min. tR = 30 min. 
1
H NMR (600 MHz, DMSO-d6) δ 6.46 (s, 1H), 6.37 (s, 1H), 6.27 (d, J = 2.0 Hz, 1H), 5.58 (t, J = 2.0 
Hz, 1H), 4.32 (s, 1H), 4.16 (s, 1H), 3.15 (s, 1H), 2.85-2.84 (m, 1H), 2.61-2.59 (m, 1H), 2.52-2.51 (m, 
2H), 1.81 (s, 6H), 1.70-1.62 (m, 3H), 1.52 (s, 1H), 1.45-1.39 (m, 2H), 1.31 (s, 12H). 
13
C NMR (150 Hz, DMSO-d6) δ 192.7, 192.2, 171.9, 163.2, 156.1, 151.8, 108.4, 105.5, 80.9, 61.5, 
59.7, 55.8, 33.7, 28.4, 28.3, 25.1, 25.1, 24.8, 24.0. 
HRMS (ESI, pos.) m/z: [M + Na]
+
 calcd for C28H36N2NaO13Rh2S, 868.9946; found: 868.9945. 
 
Synthesis of catalyst 3 
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Compounds 3a, 3b, 3c, and 3d were prepared using the same procedures as described in reference 37. 
Catalyst 3 was synthesized using the same procedures as described for catalyst 2. 
 
Catalyst 3 
 
1
H NMR (600 MHz, DMSO-d6) δ 6.59 (s, 2H), 6.47-6.45 (m, 2H), 6.37 (s, 1H), 4.32 (s, 1H), 4.16 (s, 
1H), 3.15 (s, 1H), 2.85-2.84 (m, 1H), 2.61-2.59 (m, 1H), 2.54 (s, 6H), 1.78 (s, 6H), 1.67-1.61 (m, 3H), 
1.52 (s, 1H), 1.41-1.40 (m, 2H), 0.91 (s, 12H). 
13
C NMR (150 Hz, DMSO-d6) δ 196.7, 191.0, 171.6, 162.7, 149.1, 138.8, 127.7, 120.8, 61.0, 59.1, 
55.3, 45.8, 45.8, 40.4, 33.3, 27.9, 25.2, 24.3, 23.5. 
HRMS (ESI, pos.) m/z: [M + Na]
+
 calcd for C30H40N2NaO11Rh2S, 865.0361; found: 865.0354. 
 
Synthesis of catalyst 4 
 
Compound 4a, 4b, 4c and catalyst 4 were prepared using the same procedures as described for 
compound 1a, 1b, 2c, 1. 
diethyl 2,2'-((4-formyl-1,3-phenylene)bis(oxy))bis(2-methylpropanoate) 4a       
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2,4-dihydroxybenzaldehyde (0.691 g, 5 mmol, 1.0 equiv.) was added to a flame-dried round bottom 
flask charged with a magnetic stir bar, along with K2CO3 (3.32 g, 24 mmol, 4.8 equiv.) and KI (0.83 g, 
5 mmol, 1.0 equiv.). The solid reagents were then dissolved in 20 mL dry DMF under N2. Ethyl 2-
bromo-2-methylpropanoate (2.93 mL, 20 mmol, 4.0 equiv.) was then added dropwise to the reaction 
mixture. The reaction was heated to 60 °C overnight. After cooling to rt, the mixture was quenched 
with a saturated NH4Cl solution and diluted with 20 mL H2O and 20 mL Et2O. The aqueous layer was 
extracted twice with Et2O (20 mL × 2). The organic layer was collected, dried with Na2SO4 and 
concentrated. The crude product was purified by flash chromatography (EtOAc / cyclohexane = 1 / 5 ~ 
1 / 4) to afford the product 4a (0.73 g, 40%) as a colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 10.33 (s, 1H), 7.75 (d, J = 8.7 Hz, 1H), 6.46 (dd, J = 8.7, 2.1 Hz, 1H), 
6.20 (d, J = 2.2 Hz, 1H), 4.29-4.20 (m, 4H), 1.66 (s, 6H), 1.62 (s, 6H), 1.27-1.21 (m, 6H). 
13
C NMR (100 Hz, CDCl3) δ 188.9, 173.5, 161.7, 159.8, 129.7, 121.7, 111.7, 106.6, 80.4, 79.7, 62.0, 
61.9, 25.6, 25.6, 14.1. 
HRMS (ESI, pos.) m/z: [M + Na]
+
 calcd for C19H26NaO7, 389.1576; found: 389.1576. 
 
2,2'-((4-formyl-1,3-phenylene)bis(oxy))bis(2-methylpropanoic acid) 4b    
 
Diester 4a (0.159 g, 0.434 mmol, 1 equiv.) and LiOH · H2O (0.182 g, 4.34 mmol, 10 equiv.) were 
dissolved in MeOH / H2O = 4 / 1 (5 mL). The mixture was heated at 60 °C for 3 h. After cooling to rt, 
the mixture was acidified with 1 M HCl solution to pH 1 and extracted with EtOAc (20 mL × 3). The 
organic layer was washed with brine and dried over Na2SO4. Concentration under reduced pressure 
yielded diacid 4b (0.13 g, 97%) as light yellow solid. 
1
H NMR (400 MHz, CDCl3) δ 10.36 (br, 2H), 10.19 (br, 1H), 7.72 (d, J = 8.8 Hz, 1H), 6.56 (ddd, J = 
8.6, 2.2, 0.7 Hz, 1H), 5.94 (d, J = 2.2 Hz, 1H), 1.66 (s, 6H), 1.63 (s, 6H). 
13
C NMR (100 Hz, CDCl3) δ 188.7, 177.8, 177.7, 160.9, 158.5, 131.1, 120.4, 113.0, 103.5, 79.4, 78.9, 
25.4, 25.3. 
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HRMS (ESI, pos.) m/z: [M + Na]
+
 calcd for C15H18NaO7, 333.0950; found: 333.0942. 
 
Dirhodium complex 4c 
                  
A round bottom flask was charged phenol diacid 4b (30.7 mg, 0.099 mmol, 1.1 equiv.), (cis)-
Rh2(OAc)2(OCOCF3)2 (49.5 mg, 0.09 mmol, 1 equiv.) and K2CO3 (24.9 mg, 0.18 mmol, 2 equiv.). 
THF (10 mL) was added and the mixture was heated to 50 °C for 3 h. The solvent was removed under 
reduced pressure and the crude mixture was purified by flash chromatography (EtOAc / cyclohexane = 
1 / 1) to afford complex 4c (44 mg, 77%) as a green solid. 
1
H NMR (400 MHz, CD3OD) δ 10.65 (s, 1H), 7.62 (d, J = 8.8 Hz, 1H), 6.47 (ddd, J = 8.7, 2.3, 0.9 Hz, 
1H), 5.65 (d, J = 2.2 Hz, 1H), 1.82 (s, 6H), 1.46-1.43 (m, 12H). 
13
C NMR (100 Hz, CD3OD) δ 192.8, 192.7, 192.4, 190.1, 163.2, 161.2, 129.8, 121.5, 114.2, 106.5, 
82.3, 81.6, 61.9, 52.0, 31.3, 28.9, 28.0, 25.7, 23.0. 
HRMS (ESI, pos.) m/z: [M + Na]
+
 calcd for C19H22NaO11Rh2, 654.9170; found: 654.9162. 
 
Catalyst 4 
                  
To a solution of complex 4c (10.8 mg, 17 µmol, 1.0 equiv.) and biotin hydrazide 7a (4.4 mg, 17 µmol, 
1.0 equiv.) in dry DMSO (1 mL), TFA (1.3 µL, 17 µmol, 1.0 equiv.) was added. The reaction mixture 
was stirred for 3h at rt. After dilution with MeCN / H2O = 1 / 2 (3 mL), the crude reaction mixture was 
purified by preparative HPLC to afford catalyst 4 (10 mg, 67%) as light purple solid. HPLC gradient: 
MeCN / H2O, 10% to 70% for 40 min. tR = 21 min. 
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One isomer:  
1
H NMR (600 MHz, DMSO-d6) δ 11.22 (s, 1H), 8.28 (s, 1H), 7.66 (d, J = 4.0 Hz, 1H), 6.56-6.55 (m, 
1H), 6.44 (s, 1H), 6.35 (s, 1H), 5.68 (d, J = 2.3 Hz, 1H), 4.31-4.30 (m, 1H), 4.15-4.13 (m, 1H), 3.13 
(m, 1H), 2.84-2.83 (m, 1H), 2.59 (s, 1H), 2.16 (t, J = 7.4 Hz, 2H), 1.81 (s, 6H), 1.68-1.56 (m, 4H), 
1.52-1.46 (m, 2H), 1.34-1.32 (m, 12H). 
13
C NMR (150 Hz, DMSO-d6) δ 191.7, 192.1, 173.9, 168.2, 162.7, 156.5, 141.0, 126.1, 119.4, 115.2, 
107.8, 81.2, 61.0, 59.1, 55.4, 40.0, 34.0, 28.8, 28.3, 25.0, 24.6, 23.5. 
Other isomer:  
1
H NMR (600 MHz, DMSO-d6) δ 11.04 (s, 1H), 8.15 (s, 1H), 7.64 (d, J = 4.0 Hz, 1H), 6.54-6.52 (m, 
1H), 6.43 (s, 1H), 6.35 (s, 1H), 5.64 (d, J = 2.3 Hz, 1H), 4.31-4.30 (m, 1H), 4.15-4.13 (m, 1H), 3.13 
(m, 1H), 2.82-2.81 (m, 1H), 2.57 (s, 1H), 2.16 (t, J = 7.4 Hz, 2H), 1.81 (s, 6H), 1.68-1.56 (m, 4H), 
1.52-1.46 (m, 2H), 1.34-1.32 (m, 12H). 
13
C NMR (150 Hz, DMSO-d6) δ 191.7, 192.2, 174.5, 173.9, 162.7, 156.6, 138.4, 125.8, 118.9, 115.2, 
107.3, 80.9, 61.0, 59.2, 55.4, 40.0, 34.0, 28.8, 28.3, 25.0, 24.6, 23.5. 
HRMS (ESI, pos.) m/z: [M + Na]
+
 calcd for C29H38N4NaO12Rh2S, 895.0215; found: 895.0211. 
 
Synthesis of catalyst 5 
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Compound 7c was prepared according to the reported procedure.
38
 
catalyst 5 
                                         
Rh2(OAc)3(OCOCF3) (7.6 mg, 15.3 µmol, 1 equiv.), compound 7c (5.6 mg, 15.3 µmol, 1 equiv.) and 
N, N-Diisopropylethylamine (3.2 µL,  18.4 µmol, 1.2 euquiv.) were added into a round bottom flask. 
Dry DMSO (1 mL) was charged and the mixture was heated to 50 °C for 2 h. The reaction mixture 
was subjected to preparative HPLC for purification. Final product 5 (5.7 mg, 50%) was obtained as 
light purple solid. HPLC gradient: MeCN / H2O, 2% to 60% for 40 min. tR = 19 min. 
1
H NMR (600 MHz, DMSO-d6) δ 10.12 (s, 1H), 7.71 (d, J = 8.8 Hz, 2H), 7.59 (d, J = 8.8 Hz, 2H), 
6.42 (s, 1H), 6.35 (s, 1H), 4.31-4.29 (s, 1H), 4.13 (s, 1H), 3.12-3.11 (m, 1H), 2.83-2.80 (m, 1H), 2.62-
2.56 (m, 1H), 2.31 (t, J = 7.0 Hz, 2H), 1.84 (s, 3H), 1.77 (m, 6H), 1.67-1.55 (m, 3H), 1.50-1.48 (s, 1H), 
1.40-1.30 (m, 2H). 
13
C NMR (150 Hz, DMSO-d6) δ 191.4, 191.3, 184.3, 171.6, 162.7, 143.0, 129.5, 125.4, 117.8, 61.0, 
59.2, 55.4, 40.4, 36.3, 28.2, 28.0, 24.9, 23.7, 23.6. 
HRMS (ESI, pos.) m/z: [M + Na]
+
 calcd for C23H29N3NaO10Rh2S, 767.9581; found: 767.9577. 
 
Synthesis of catalyst 6 
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Compound 7d and 6 were synthesized in the same way using 7c and 5 respectively. 
Catalyst 6 
                                   
Rh2(OAc)3(OCOCF3) (9.9 mg, 20 µmol, 1 equiv.), compound 7d (8.0 mg, 22 µmol, 1.1 equiv.) and N, 
N-Diisopropylethylamine (4.2 µL,  24 µmol, 1.2 equiv.) was charged into a round bottom flask. 
DMSO (1 mL) was charged and heated to 50 °C for 2 h. The reaction mixture was purified by 
preparative HPLC. The pure product 6 (7.5 mg, 50%) was obtained as light purple solid. HPLC 
gradient: MeCN / H2O, 2% to 50% for 40 min. tR = 25 min. 
1
H NMR (600 MHz, DMSO-d6) δ 9.99 (s, 1H), 8.09 (s, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.42 (d, J = 7.8 
Hz, 1H), 7.30 (t, J = 7.9 Hz, 1H), 6.44 (s, 1H), 6.37 (s, 1H), 4.32 (s, 1H), 4.15 (s, 1H), 3.14-3.08 (m, 
1H), 2.84-2.83 (m, 1H), 2.60-2.58 (m, 1H), 2.30 (t, J = 7.0 Hz, 2H), 1.84 (s, 3H), 1.78 (m, 6H), 1.67-
1.57 (m, 3H), 1.52 (s, 1H), 1.42-1.32 (m, 2H). 
13
C NMR (150 Hz, DMSO-d6) δ 191.5, 191.3, 184.4, 171.4, 162.7, 139.1, 131.3, 128.5, 122.8, 122.6, 
118.8, 61.0, 59.2, 55.4, 40.3, 36.3, 28.1, 28.0, 25.1, 23.6, 23.6. 
HRMS (ESI, pos.) m/z: [M + Na]
+
 calcd for C23H29N3NaO10Rh2S, 767.9581; found: 767.9584. 
 
Synthesis of the C-H insertion substrate 10 and product 11 
 
2, 2, 2-trifluoroethyl 2-phenylacetate 12 
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2,2,2-Trifluoroethanol (0.57 mL, 7.5 mmol, 1.5 equiv.) and pyridine (0.8 mL, 10 mmol, 2 equiv.) were 
dissolved in 25 mL dry Et2O and stirred for 20 min. Phenylacetyl chloride (0.66 mL, 5 mmol, 1 equiv.) 
was slowly added at 0 °C and the reaction mixture was stirred overnight at rt. The reaction was 
quenched with water and extracted with Et2O (30 mL × 3). The crude mixture was concentrated and 
purified by flash column chromatography (EtOAc / cyclohexane = 1 / 10 ~ 1 / 8) to yield the product 
(82%) as white solid. Spectral data for 12 was identical to those previously reported.
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1
H NMR (400 MHz, CDCl3) δ 7.33-7.29 (m, 5H), 4.47 (q, J = 8.4 Hz, 2H), 3.73 (s, 2H). 
 
2, 2, 2-trifluoroethyl 2-diazo-2-phenylacetate 10 
 
Compound 13 (0.2367 g, 1.1 mmol, 1.0 equiv.) was dissolved in acetonitrile (20 mL) together with p-
ABSA (0.39 g, 1.63 mmol, 1.5 equiv.) and the solution cooled to 0 °C. Then, DBU (0.32 mL, 2.17 
mmol, 2.0 equiv.) was added drop-wise. The solution was stirred for 6 hours at rt and quenched with 
saturated aqueous NH4Cl (15 mL) and H2O (20 mL). The solution was extracted with Et2O (20 mL × 3) 
and the organic layer separated, dried over Na2SO4, and concentrated. The crude material was purified 
by column chromatography (Et2O / cyclohexane = 1 / 20) to give the diazo as a yellow solid (85.2 mg, 
32% yield). 
1
H NMR (400 MHz, CDCl3) δ 7.48-7.39 (m, 4H), 7.25-7.21 (m, 1H), 4.65 (q, J = 8.3 Hz, 2H). 
13
C NMR (100 Hz, CDCl3) δ 129.1, 126.4, 124.5, 124.3, 124.1, 121.5, 60.3 (q, J = 36.7 Hz). 
19
F NMR (376.5 MHz, CDCl3) δ -73.5 (t, J = 8.4 Hz, 3F). 
 
2, 2, 2-trifluoroethyl 2-(cyclohexa-2, 5-dien-1-yl)-2-phenylacetate 11 
 
Diazo 10 (48.8 mg, 0.2 mmol, 1 equiv.) and 1, 4-cyclohexadiene (97.5 µL, 1 mmol, 5 equiv.) were 
charged into a 1.5 mL vial and cooled to 0 °C. Rh2(S-DOSP)4 (1.32 mg, 0.002 mmol, 1 mol%) was 
carefully added to the mixture. The reaction mixture was stirred for 30 min at 0 °C and subjected to 
column chromatography (Et2O / cyclohexane = 1 / 20) for purification. The product 11 was obtained 
(78% yield) as colorless oil. 
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1
H NMR (400 MHz, CDCl3) δ 7.37-7.28 (m, 5H), 5.86-5.81 (m, 1H), 5.73-5.68 (m, 2H), 4.62-4.52 (m, 
1H), 4.41-4.31 (m, 1H), 3.35-3.46 (m, 2H), 2.64-2.60 (m, 2H). 
13
C NMR (100 Hz, CDCl3) δ 171.4, 135.7, 128.6, 127.7, 126.8, 126.3, 125.8, 125.3, 60.3 (q, J = 36.7 
Hz), 57.9, 38.5, 26.4. 
19
F NMR (376.5 MHz, CDCl3) δ -73.0 (t, J = 8.4 Hz, 3F). 
HRMS (ESI, pos.) m/z: [M +Na]
+
 calcd for C16H15F3NaO2, 319.0922; found: 319.0920. 
 
General procedure of cyclopropanation (styrene and 8a) and C-H insertion (10 and 1, 4-
cyclohexadiene) catalyzed by the artificial carbene transferase 
cyclopropanation (styrene with 8a or 8b) 
 
A series of stock solutions were prepared: biotinylated dirhodium catalyst (4 mM in DMSO), 
streptavidin stock (biotin binding sites 800 M in MQ water), styrene stock (0.8 M in DMSO), ethyl 
diazoacetate 8a or diazo(phenyl)acetate 8b stock (2.4 M in DMSO) and MOPS buffer (0.2 M, pH 7.0). 
In a small glass reaction vial, MOPS buffer stock solution (200 L), protein stock solution (100 L),  
catalyst DMSO stock solution (10 L) and MQ water (80 µL) were added and incubated at 25 °C for 
10 min. Then, the styrene stock solution (5 μL) and the diazo compound stock solution (5 μL) were 
added, and the reaction mixture was shaked in a ThermoMixer for 16 h at 25 °C. 
Upon completion of the reaction, the mixture was quenched with a pyridine solution (10 μL, 1 M in 
H2O) and the internal standard 1, 3, 5-Trimethoxybenzene (50 L, 100 mM in ethyl acetate) was 
added, followed by EtOAc (950 L). The mixture was thoroughly shaken, and the upper organic phase 
was transferred to an eppendorf tube, dried with Na2SO4 and centrifuged at 14’000 rpm for 10 minutes. 
The supernatant (700 μL) was transferred in an HPLC vial and subjected to GC analysis to determine 
the conversion. 
GC analysis. Column: Agilent CP-Chirasil-Dex CB column. Method: Vinjected: 1 μL. Catalysis samples 
were introduced into the instrument via a split (1:20) injection at a flow rate of 1.7 mL/min helium gas.  
The temperature program used for product 9a: 130 °C for 20 minutes. TR 9.0 min (internal standard 1, 
3, 5-Trimethoxybenzene), 11.3 min (product cis isomer), 12.3 min (cis isomer), 12.8 min (trans 
isomer), 13.3 min (trans isomer). 
66 
 
The temperature program used for product 9b: 170 °C for 30 minutes. TR 3.4 min (internal standard 1, 
3, 5-Trimethoxybenzene), 15.3 min (product cis isomer), 16.1 min (cis isomer). 
 
 
 
C-H insertion (10 and 1, 4-cyclohexadiene) 
 
In a small glass vial, MOPS buffer stock solution (200 L), protein stock solution (100 L), catalyst 
DMSO stock solution (10 L) and MQ water (80 µL) were added and incubated at 25 °C for 10 min. 
Then, the diazo stock solution (5 μL) and 1, 4-cyclohexadiene stock solution (5 μL) were added, and 
the reaction mixture was shaken in a ThermoMixer for 16 h at 25 °C. 
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The mixture was then quenched with a pyridine solution (10 μL, 1 M in H2O) and the internal standard 
1, 3, 5-Trimethoxybenzene (50 L, 100 mM in ethyl acetate) was added, followed by EtOAc (950 L). 
The solution mixture was thoroughly mixed and the upper organic layer was transferred to an 
eppendorf tube, dried with Na2SO4 and centrifuged at 14’000 rpm for 10 minutes. The supernatant 
(700 μL) was transferred in an HPLC vial and subjected to GC analysis to determine the conversion. 
GC analysis. Column: Agilent HP-1 column. Method: Vinjected: 1 μL. Catalysis samples were injected 
via a split (1:20) injection at a flow rate of 1.7 mL/min helium gas. The temperature program for 
product 11: 170 °C for 20 minutes. TR 2.7 min (internal standard 1, 3, 5-Trimethoxybenzene), 4.6 min 
(product). 
 
 
ICP-MS analysis for dirhodium uptake in the periplasm screening  
In order to quantify the rhodium content of the cells, ICP-MS measurements were performed in 
duplicate using our reported protocol.
18
 Measured and calculated results are shown in table 1. 
Table 1 Rhodium uptake determined by ICP-MS upon incubation of catalyst 2 with E. coli cells 
secreting Sav in their periplasm of E. coli cells. Based on the [Rh] determined by ICP-MS, the 
corresponding TON can be determined. 
 
rhodium  added 
during for incubation 
(nmol) 
amount of Rh 
determined after 
incubation and washing 
(nmol) 
Uptake (%) calculated TON 
empty 50 3.2 ± 0.3 6 ± 1 10 ± 3 
WT 50 8.3 ± 0.8 17 ± 2 9 ± 0 
S112C 50 6.4 ± 0.1 13 ± 0 17 ± 3 
S112D 50 6.0 ± 0.5 12 ± 1 11 ± 3 
y = 0.1095x 
R² = 0.999 
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product concentration (mM) 
calibration curve for C-H insertion product 11 
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K121C 50 8.0 ± 0.2 16 ± 0 20 ± 2 
K121M 50 8.9 ± 0.1 18 ± 0 11 ± 3 
 
General procedure for cyclopropanation screening in the periplasm of E. coli 
The TOP10(DE3)_pET30 E. coli strain and kanamycin antibiotic were used for the expression of 
periplasmic OmpA tagged Sav WT, S112C, S112D, K121C and K121M. An overnight culture of the 
above mutants was inoculated to a main culture (50 mL modified ZYM-5052 rich induction medium
6 
in 250 mL erlenmeyer flask) for 3 h shaking (37 °C, 220 rpm). Then, the cultures were induced by 
IPTG (final concentration 50 µM) and continued shaking for 4 h (25 °C, 220 rpm) to express and 
secrete the periplasmic Sav. 
The cells were harvested into a 96-well plate by transferring OD 3/mL cells to each well on the plate. 
The plate was centrifuged (3200 g, 4 °C, 20 min) and the supernatant was discarded. The cell pellets 
were washed with MOPS buffer (50 mM, NaCl 0.9%, pH 7.0), spun down and the supernatant was 
discarded. Then, the cell pellets were incubated in the above MOPS buffer containing additional 50 
µM dirhodium catalyst 2 on ice for 0.5 h. The plate was centrifuged and the supernatant was discarded, 
followed by a second wash with MOPS buffer. The catalysis buffer in MOPS (200 µL of 0.2 M stock 
solution, pH 7.0) was added into each well. The individual cell pellets were resuspended and 
transferred to HPLC glass vials. Then styrene and the diazo substrate were added to the glass vials and 
the catalysis was performed at 25 °C for 16 h. The workup and the GC analysis allowed to quantify the 
activity of each mutant. 
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3.6   Comments on dirhodium complexes 
(a) To form efficient dirhodium-based ArMs, the protein scaffold should have large enough active site 
to accommodate the large dirhodium mioety. Whether the dirhodium could denature the protein or 
protein residues could in turn affect the dirhodium need to be carefully evaluated. 
(b) The dirhodium moiety should be bound to protein scaffold tightly and at the right distance of the 
surrounding residues. Directed evolution is a good way to identify hotspots for activity and selectivity 
improvement. As dirhodium core is stable in cellular environment, using cell lysates or whole cells 
directly for catalysis may help to increase the thoughput of the screening.  
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4.1   Abstract 
Artificial metalloenzymes (ArMs), which combine an abiotic metallocofactor with a protein scaffold, 
catalyze various synthetically useful transformations. To complement the natural enzymes’ repertoire, 
effective optimization protocols to improve ArM’s performance are required. Here we report on our 
efforts to optimize an artificial transfer hydrogenase’s activity (ATHase) using E. coli whole cells. For 
this purpose, we rely on a self-immolative quinolinium substrate surrogate which, upon reduction, 
releases fluorescent umbelliferone, thus allowing efficient screening. After four rounds of directed 
evolution in the presence of E. coli whole cells, the evolved ATHase displayed up to fivefold increase 
in its transfer hydrogenation activity compared to the wild-type ATHase. 
 
4.2   Introduction 
Directed evolution is a powerful means to optimize the performance of genetically-encoded proteins.1-
5 In recent years, both natural and artificial enzymes have been engineered by directed evolution to 
catalyze a variety of new-to-nature reactions.6-14 Artificial metalloenzymes (ArM) result from the 
introduction of an abiotic metallocofactor within a protein scaffold. In this context, hemoproteins15,16, 
streptavidin (Sav hereafter)7,17 and Pfu prolyl-oligopeptidase11,12 have proven most versatile. The most 
active ArM reported to date rely on precious metal cofactors, which are frequently poisoned by the 
presence of thiols.18-21 Critical analysis of a typical workflow used for the directed evolution of ArMs 
reveals the following bottlenecks: i) need to perform catalysis either using purified protein samples or 
in a thiol-free environment (i.e. outside the cytoplasm which contains mM concentrations of 
glutathione in aerobic cells), ii) HPLC analysis of the reaction outcome is often time-consuming.  
Herein, we report on our efforts to address both the above challenges by compartmentalizing an 
artificial transfer-hydrogenase (ATHase hereafter) in the periplasm of E. coli and relying on a self-
immolative substrate surrogate that releases a fluorophore upon reduction of its iminium moiety. 
 
4.3   Results and discussion 
Self-immolative substrates consist of a cap, a self-immolative core and a leaving group.
22
 A catalytic 
reaction modifies the cap which, in turn, triggers the release of the leaving group, via the intermediary 
of the self-immolative core, Figure 1a.
23
 Self-immolative substrates have found wide applications in 
bioanalysis
24
, prodrugs
25,26
, high-throughput screening or biomolecular imaging
27
 etc. We 
hypothesized that we could design a quinoline substrate that, upon N=C reduction, would undergo 
self-immolation to release a fluorophore via the formation of iminoquinone-methide intermediate,
28
 
Figure 1b. Although several anchoring strategies and protein scaffolds have been exploited for the 
90 
 
creation of ATHase,
29-31
 we selected the biotin-streptavidin couple to ensure localization of the Ir-
based cofactor. Analysis of the various X-ray structures [Cp*Ir(biot-p-L)Cl] · Sav,
32,33
 reveals that the 
cofactor, located in the biotin-binding vestibule, is solvent exposed. We reasoned that introduction of 
additional structural elements around the biotin-binding vestibule may have a significant impact on the 
catalytic performance.
34
 Thanks to its stability and plasticity, we have shown that Sav is remarkably 
tolerant towards the modification of its loops.
35
 Having repeatedly reported that mutations within the 
7,8-loop (residues between 112 and 124) had the strongest effect on catalytic performance of various 
ArM based on the biotin-streptavidin technology,
36,37
 we selected a 24-residue helix-turn-helix motif 
(foldit player design, FPD) designed by Baker group
38
 (Figure 2a), and set out to insert it between 
residues 115 and 117 of Sav WT, Figure 2. The structure of the [(Cp*Ir(biot-p-L)Cl] · Sav-FPD was 
modelled using Rosetta.
39
 To our delight, the FPD-chimera could be expressed as a soluble fraction in 
E. coli and purified by affinity chromatography on an iminobiotin-sepharose matrix, thus highlighting 
its biotin-binding affinity (See SI for details). To circumvent the irreversible poisoning of the precious 
metal cofactor by glutathione,
40,41
 we set out to secrete the Sav-FPD chimera to the periplasm by 
fusing it with the OmpA N-terminal signal peptide. SDS-PAGE analysis of E. coli cells containing the 
OmpA-Sav-FPD construct confirmed the localization of the soluble biotin-binding protein within its 
periplasm (Figure SI_Figure 1). As E. coli’s periplasm contains significantly lower glutathione 
concentrations than in its cytoplasm, and the equilibrium lies mostly to the oxidized disulfide form, we 
anticipated that the assembled [(Cp*Ir(biot-p-L)Cl] · Sav-FPD would maintain its ATHase activity in 
the periplasm, as we have recently demonstrated for metathesis using a biotinylated Ru-cofactor.
40
  
 
Figure 1. (a) General concept of a self-immolative substrate. (b) Reduction of the quinolinum moiety in substrate 
1 leads to the release of umbelliferone 2 which can be detected by fluorescence. 
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Figure 2. Introducing an additional structural motif around the biotin-binding vestibule may influence ATHase 
activity. (a) Cartoon representation of the FPD loop and its sequence; the residues highlighted in red were 
subjected to saturation mutagenesis. (b) Crystal structure of Sav S112A assembled with [Cp*Ir(biot-p-L)Cl] · 
Sav complex (PDB: 3PK2). (c) Modelled structure [Cp*Ir(biot-p-L)Cl] · Sav-FPD. 
Following the E. coli culture using a modified ZYM5052 rich medium, the cells were incubated (30 
min on the ice) with the buffer containing [(Cp*Ir(biot-p-L)Cl] and washed twice to remove the 
unbound cofactor (See SI for details). Next, the cell pellet was resuspended in a solution containing 
formate (1 M) and the substrate 1 (1 mM). Unfortunately, no conversion could be detected after 16 
hours at 25 °C, either by fluorescence (322 nm excitation, 440 nm fluorescence of umbelliferone 2) or 
by UPLC-MS. Speculating that the low concentrations of glutathione present in the periplasm may 
suffice to irreversibly poison [(Cp*Ir(biot-p-L)Cl], we added diamide (2 mM) to fully oxidize 
glutathione. Again here, no conversion could be observed. Inspired by the Cu(II)-catalyzed glutathione 
oxidation,42,43 we treated the E. coli cells with [Cu(gly)2] (2 mM), both at harvest and in the catalysis 
buffer. To our delight, the uncaging of umbelliferone 2 was observed when this protocol was applied. 
Thanks to the good Sav-FPD expression levels in E. coli’s periplasm, and the sensitivity of the 
fluorescence-based monitoring of catalysis, the entire screening procedure could be carried out in a 96-
well plate format, Figure 3.  
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Figure 3. Assembling and screening ATHase in E. coli whole cells. (a) Localization of Sav-FPD chimeras within 
the periplasm of E. coli allows to screen whole cells for ATHase activity upon incubation with [Cp*Ir(biot-p-
L)Cl] using self-immolative quinolinium substrate surrogate 1. (b) Addition of [Cu(gly)2] significantly improves 
ATHase activity in E. coli. 
Past experience with [(Cp*Ir(biot-p-L)Cl] · Sav highlighted the detrimental influence of the K121 
residue on ATHase activity.21,44 We hypothesized that this residue may also affect catalytic activity of 
[(Cp*Ir(biot-p-L)Cl] · Sav-FPD. Gratifyingly, upon addition of 2 µM cofactor and 2 mM [Cu(gly)2], 
the catalytic performance of [(Cp*Ir(biot-p-L)Cl] · Sav-FPD K121A was markedly improved 
compared to [(Cp*Ir(biot-p-L)Cl] · Sav-FPD (5% conversion and 26% conversion respectively after 
16 hours), Figure 3. This result prompted us to optimize the catalytic activity by directed evolution. 
We thus built a mutant library relying on the use NHT codons (encode amino acids A, N, D, H, I, L, F, 
P, S, T, Y, V) for mutations at the following positions: S112, K121, FPD(K9) and FPD(N11), Figure 
2a. The NHT primers code mostly for hydrophobic residues, which have most often been shown to 
positively influence the catalytic performance of ArM based on the biotin-streptavidin technology.36,37  
In order to ensure full coverage at positions S112 and K121 (i.e. 12 · 12 = 144 mutants), we mutated 
simultaneously both positions. Accordingly, 450 clones were screened and the best hits were 
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sequenced. Eight replicates were tested independently revealing that Sav-FPD S112V-K121A 
performs best. It was thus selected as the template for the next generation for FPD-centered 
mutagenesis. The positions K9 and N11, which are part of the FPD loop, were randomized 
sequentially using NHT codons. Unfortunately, none of the triple or quadruple mutants screened 
outperformed [(Cp*Ir(biot-p-L)Cl] · Sav-FPD S112V-K121A chimera for the reduction of the 
quinolinium substrate surrogate 1 after screening 600 clones, Figure 4. 
 
Figure 4. Directed evolution of ATHase using quinolinium substrate 1. (a) Summary of the streamlined 
screening protocol for random mutagenesis at positions S112X and K121Y using NHT codons. (b) 8-replicate 
comparison for the most promising mutants (c) 96-well plate directed evolution protocol. 
The observed whole cell ATHase improved activity may result from a combination of two factors: i) 
improved activity of the Sav-FPD chimera and/or ii) higher protein production levels of the 
recombinant protein in the periplasm. Screening with purified Sav samples in vitro, allows to 
deconvolute both these factors and identify the Sav-FPD’s activity improvement resulting from the 
directed evolution. Accordingly, the in vitro ATHase activity towards four imine substrates 4a-7a were 
tested and the results are summarized in Figure 5.  
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Figure 5. Substrate scope for ATHase using mutants identified using self-immolative substrate 1. Conversions 
and ee where determined either by HPLC (substrates 4a, 5a, 6a) or GC (for 7a) (See SI for details).  
The results of the screening using purified Sav-FPD samples with prochiral substrates 4a-7a reveal 
several striking features: i) Compared to Sav WT, introduction of the FPD structural motif (Sav-FPD) 
has a positive impact on the turnover numbers after 24 hours (TON). Up to a fivefold higher TON is 
observed for the salsolidine precursor 4a. ii) Introduction of mutations at the base of loop 7,8 (i.e. Sav-
FPD S112V-K121A) positively influences TON for three imine substrates: 5a, 6a and 7a. iii) These 
mutations also significantly influence the enantioselectivity of the reduction, especially in the case of 
imine 4a. It should be emphasized that the screening protocol focused on improving TON, not ee. iii) 
Mutations within the FPD motif have ambivalent effects: while Sav-FPD(K9L-N11P) S112V-K121A 
leads to a significant decrease in TON for all substrates, the Sav-FPD(K9I-N11P) S112V-K121A 
affords good TON in most cases.  
 
4.4   Conclusion 
With the aim of developing a streamlined protocol for the directed evolution of ATHases using E. coli 
whole cells, we report herein three important developments. i) Asymmetric transfer hydrogenation 
using the [(Cp*Ir(biot-p-L)Cl] · Sav ArM can be performed in the periplasm of E. coli, upon addition 
of [Cu(gly)2]. We hypothesize that this contributes to oxidize the glutathione present in the periplasm. 
ii) The introduction of a 24 aminoacid helix-loop-helix in the immediate proximity of the biotin-
binding vestibule has a positive effect of the catalytic performance of [(Cp*Ir(biot-p-L)Cl] · Sav-FPD 
as reflected by the increased TON (up to fivefold improvement). iii) The performance of the ATHase 
can be improved by directed using E. coli whole cells. Upon relying on the self-immolative 
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quinolinium substrate 1, the entire screening protocol can be carried out in a 96 well plate format, 
from protein expression to fluorescent readout. Current efforts are aimed at characterizing by X-ray 
the evolved [(Cp*Ir(biot-p-L)Cl] · Sav-FPD and adapting this protocol to improve both the activity 
and the (pseudo)-enantioselectivity of ATHase based on the biotin-streptavidin technology. 
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4.5   Supporting information 
Synthesis of quinolinium substrate 1 
7-((2-methylquinolin-6-yl)methoxy)-2H-chromen-2-one 8 
 
To a 50 mL two-necked round-bottom flask, umbelliferone (107 mg, 0.66 mmol, 1.1 equiv.) and 
Cs2CO3 (342 mg, 1.05 mmol, 1.75 equiv.) were added. The flask was evacuated and charged with N2 
three times. Under a mild N2-flow, MeCN (30 mL) was added and the reaction mixture was stirred at 
rt for 20 min. Several small portions of 6-(bromomethyl)-2-methylquinoline (142 mg, 0.6 mmol, 1 
equiv.) were slowly added into the flask and the mixture was stirred for another 5 h. The solvent was 
removed under reduced pressure, and the resulting crude mixture was purified by flash 
chromatography (EtOAc / cyclohexane = 1 / 1 ~ 2 / 1) to afford product 8 (137.5 mg, 72% yield) as 
white solid.  
1
H NMR (400 MHz, DMSO-d6) δ 8.28 (d, J = 8.4 Hz, 1H), 8.03 – 7.95 (m, 3H), 7.80 (dd, J = 8.7, 2.0 
Hz, 1H), 7.66 (d, J = 8.6 Hz, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.15 (d, J = 2.4 Hz, 1H), 7.08 (dd, J = 8.6, 
2.4 Hz, 1H), 6.30 (d, J = 9.5 Hz, 1H), 5.41 (s, 2H), 2.67 (s, 3H). 
13
C NMR (100 Hz, DMSO-d6) δ 161.4, 160.2, 159.0, 155.3, 146.8, 144.3, 136.2, 133.6, 129.5, 129.2, 
128.4, 126.6, 125.9, 122.5, 113.0, 112.6, 112.6, 101.7, 69.6, 24.8. 
HRMS (ESI, pos.) m/z: [M + H]
+
 calcd for C20H16NO3, 318.1130; found: 318.1128. 
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Compound 1   
 
Compound 8 (79 mg, 0.25 mmol, 1 equiv.) and dimethyl sulfate (474 µL, 5 mmol, 20 equiv.) were 
dissolved in toluene (20 mL). The mixture was heated at 100 °C overnight. A large amount of 
precipitates formed. After cooling to the room temperature, the precipitate was filtered, washed with 
Et2O and hexane, affording product 1 as light yellow solid (110 mg, 99% yield).  
1
H NMR (500 MHz, DMSO-d6) δ 9.09 (d, J = 8.6 Hz, 1H), 8.63 (d, J = 9.2 Hz, 1H), 8.46 – 8.41 (m, 
1H), 8.32 – 8.22 (m, 1H), 8.12 (d, J = 8.5 Hz, 1H), 8.00 (d, J = 9.3 Hz, 1H), 7.68 (d, J = 8.6 Hz, 1H), 
7.14 – 7.09 (m, 2H), 6.31 (d, J = 9.5 Hz, 1H), 5.55 – 5.52 (m, 2H), 4.44 (s, 3H), 3.07 (s, 3H). 
13
C NMR (125 Hz, DMSO-d6) δ 161.2, 161.0, 160.2, 155.3, 145.4, 144.3, 138.9, 137.6, 134.2, 129.7, 
128.2, 127.8, 125.6, 119.5, 113.1, 112.9, 112.9, 101.8, 68.5, 52.8, 23.0. 
HRMS (ESI, pos.) m/z: [M - MeSO4]
+
 calcd for C21H18NO3, 332.1281; found: 332.1284. 
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Construction of Sav-FPD mutant library for directed evolution 
TOP10(DE3)_OmpA Sav-FPD construct was obtained from the previous work.
34 
 
Table 1. Sequence of the OmpA Sav-FPD construct for periplasmic expression (the FPD loop is 
highlighted in blue) 
protein sequence MKKTAIAIAVALAGFATVAQAASMTGGQQMGRDQAGITGTWYNQLGS
TFIVTAGADGALTGTYESAVGNAESRYVLTGRYDSAPATDGSGTALGW
TVAWKNNYRNAHSATTWSGQYVGGAEARINTQWLLTSGTTSPLSEALT
KANSPAEAYKASRGAGANAWKSTLVGHDTFTKVKPSAASIDAAKKAG
VNNGNPLDAVQQ 
DNA sequence ATGAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCTGGTTTCGC
TACCGTAGCGCAGGCCGCAAGCATGACCGGTGGCCAGCAGATGGGT
CGTGATCAGGCAGGTATTACCGGCACCTGGTATAATCAGCTGGGTAG
CACCTTTATTGTTACCGCAGGCGCAGATGGTGCACTGACCGGTACGT
ATGAAAGCGCAGTTGGTAATGCAGAAAGCCGTTATGTTCTGACAGGT
CGTTATGATAGCGCACCGGCAACCGATGGTAGCGGCACCGCACTGG
GTTGGACCGTTGCATGGAAAAATAACTATCGTAATGCACATAGCGCA
ACCACCTGGTCAGGTCAGTATGTTGGTGGTGCAGAAGCACGCATTAA
TACCCAGTGGCTGCTGACCAGCGGCACCACCAGCCCGCTGAGCGAA
GCGCTGACCAAAGCGAACAGCCCGGCGGAAGCGTATAAAGCGAGCC
GCGGCGCGGGCGCAAATGCCTGGAAAAGCACCCTGGTTGGTCATGA
TACCTTTACCAAAGTTAAACCGAGCGCAGCAAGCATTGATGCAGCAA
AAAAAGCCGGTGTGAATAATGGTAATCCGCTGGATGCAGTTCAGCA
GTAATAG 
 
Mutagenesis protocol 
Four positions (S112, K121, FPD(K9) and FPD(N11)) were selected for mutagenesis using NHT 
codons. 
For the OmpA Sav-FPD S112X construct, the above OmpA Sav-FPD sequence was selected as the 
template and the S112 postion was first mutated by PCR (Q5 Hot Start DNA polymerase, forward 
primer: 5’-CTG ACC NHT GGC ACC ACC AGC CCG CTG, reverse primer: 5’-GTG CCA DNG 
GTC AGC AGC CAC TGG G) (Table 2). Afterwards, the PCR mixtures were transfered to an agarose 
gel (1% agrose) for amplification determination. The samples with amplified bands were digested by 
DpnI (20U, 1 µL) for 4 h at 37 °C. Then, the PCR products (5 µL) were transformed to TOP10(DE3) 
competent E. coli cells and plated onto LB-argar plates containing kanamycin (50 µg/mL). Colonies 
were picked for an overnight culture. Cells were harvested and the plasmids were isolated (Macherey-
Nagel NucleoSpin® Plasmid kit) and sequenced (Microsynth AG). The plasmid with the correct 
OmpA Sav FPD-S112 (NHT) was used as the template for the subsequent K121 mutation. 
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Table 2. PCR conditions 
 
1x 
MasterMix 
Final 
concentration 
MQ H2O 31.75 µL  
5x Q5 reaction buffer 10 µL  
dNTPs (10 mM) 1 µL 0.2 mM 
Forward Primer (10 µM) 1 µL 0.2 µM 
Reverse Primer (10 µM) 1 µL 0.2 µM 
Template (25 ng/µL) 1 µL 0.5 ng/ µL 
DMSO 4 µL 8% 
Q5 Hot Start (2 U/µL) 0.25 µL  
total 50 uL  
 
To prepare the OmpA Sav-FPD S112X-K121Y construct, OmpA Sav-FPD S112 (NHT) was used as 
the template. The PCR was performed (Q5 Hot Start polymerase, forward primer: 5’-CTG GNH TAG 
CAC CCT GGT TGG TCA TG, reverse primer: 5’-GGT GCT ADN CCA GGC ATT TGC GCC) 
using the protocol described above. After the digestion of PCR products, transformation, overnight 
culture, mini-prep purification and sequencing, the OmpA Sav-FPD S112 (NHT)-K121 (NHT) library 
was obtained and 450 clones were screened for their activity in the transfer hydrogenation of self-
immolative substrate 1. 
Screening results highlighted that the OmpA Sav-FPD S112V-K121A was the best mutant and it was 
used as the template for the FPD loop mutagenesis. To mutate FPD(K9) and FPD(N11) simutaneously, 
a PCR was performed (phusion polymerase, forward primer: 5’-CCN HTG CGN HTA GCC CGG 
CGG AAG CGT ATA AAG, reverse primer: 5’-CTA DNC GCA DNG GTC AGC GCT TCG CTC 
AGC G). The final OmpA Sav-FPD(K9 (NHT)-N11 (NHT)) S112V-K121A library was obtained 
using the same procedure described above. Six hundred clones of this library were screened. 
 
Directed evolution screening protocol 
The plasmid solutions of the Sav-FPD mutant library were transformed to TOP10(DE3) E. coli 
competent cells and plated on LB-argar plate with kanamycin for overnight incubation at 37 °C. To 
express the OmpA Sav-FPD mutants in a 96-deepwell plate format, LB medium (600 µL) 
supplemented with kanamycin (50 µg/mL) were inoculated from a single colony from the mutant 
library for an overnight culture. This pre-culture (30 µL) was inoculated to a main culture (1 mL) in a 
modified ZYM-5052 rich medium (kanamycin 50 µg/mL) for 4 h at 37 °C. The rest of the preculture 
solutions were mixed with glycerol (60% in MQ H2O) and the whole plate was stored at -80 °C as 
glycerol stocks. The main cultures were induced by IPTG (final concentration 50 µM) and continued 
shaking for another 4 h at 25 °C. Then these main cultures were treated with Cu(gly)2 (20 µL from 100 
mM stock, final concentration 2 mM) for 15 min. 
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The above main cultures were harvested by centrifugation (3200 g, 20 min) and washed with cold 
MOPS buffer (1 mL, 50 mM, 0.9% NaCl, pH = 7.4). After the supernatant was discarded, cell pellets 
were resuspended with 0.5 mL MOPS buffer which contains Ir cofactor (2 µM) on ice for 30 min for 
cellular uptake of cofactor. Supernatant containing excess cofactor was discarded by centrifugation 
(3200 g, 20 min). Then cell pellets were washed with MOPS buffer, spun down and the supernatant 
was discarded. 
Catalysis buffer MOPS (100 µL, 0.8 M, sodium formate 2 M, pH 7.0), H2O (80 µL) and quinolium 
substrate 1 (20 µL, 10 mM) were added to each well of 96-well plate and the cell pellets were 
resuspended. The plate was set into an incubator and shook for 16 h at 25 °C. After completion of 
catalysis, MeOH (400 µL) and H2O (400 µL) were added to the reaction mixture. Then, the plate was 
spun down (4400 rpm, 20 min) to precipitate all cell debris. The supernatant (200 µL) was transferred 
to a black 96-well plate for fluorescence measurement (λex = 322 nm, λem = 440 nm). The wells which 
displayed high fluorescence value were sequenced. 
SDS-PAGE 
To identify the expression level of periplasmic Sav, periplasmic extraction and cell lysis were 
performed for SDS-PAGE analysis. OD600 4/mL cells were transferred to eppendorf tubes, spun down 
and the supernatant was discarded. The cell pellets were resuspended in 0.25 mL TSE buffer (200 mM 
Tris-HCl, 500 mM sucrose, 1 mM EDTA, pH 8.0). The suspensions were slowly shaken at room 
temperature using a Thermo mixer (23°C, 400 rpm, 10 min), and the cells were centrifuged (10,000 g, 
4 °C, 2 min) and the supernatant was discarded. While sitting on ice, the cell pellets were carefully 
resuspended in 0.25 mL of an ice-cold MgSO4 solution (5 mM). The suspension was then incubated 
on ice for 10 min, centrifuged (10,000 g, 4 °C, 2 min) and the supernatant was collected as the 
periplasmic fraction.  
The remaining cell pellets (i.e. the cytoplasmic fraction) was lysed with a lysis buffer (100 uL, MOPS 
0.1 M, pH 7.0, lysozyme 1 mg/mL, DNase I 0.1 mg/mL) and incubated at 37 °C for 1 h. The 
suspension is centrifuged and the supernatant collected as the cytoplasmic fraction. Solutions from the 
above two fractions were analyzed by SDS gel electrophoresis using B4F (biotin-4-fluorescein) to 
reveal the biotin-binding proteins. (Figure 1) 
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Figure 1. Example of SDS-PAGE of the Sav-FPD constructs. The acrylamide gel on the left was exposed under 
UV-light in the presence of B4F. The fluorescenet bands reveal the biotin-binding ability of the Sav-FPD. The 
comassie blue-stained gel on the right reveals the good expression of Sav-FPD in the periplasmic fraction of E. 
coli cells. 
 
Large expression for promising Sav-FPD mutants 
Following the directed evolution, four Sav-FPD mutants were selected for purification: Sav-FPD, Sav-
FPD S112V-K121A, Sav-FPD(K9L-N11P) S112V-K121A, Sav-FPD(K9I-N11P) S112V-K121A.  
Table 3. Sequence of the Sav-FPD construct for cytoplamic expression (the FPD loop is highlighted in 
blue) 
protein sequence MASMTGGQQMGRDQAGITGTWYNQLGSTFIVTAGADGALTGTYESAV
GNAESRYVLTGRYDSAPATDGSGTALGWTVAWKNNYRNAHSATTWS
GQYVGGAEARINTQWLLTSGTTSPLSEALTKANSPAEAYKASRGAGAN
AWKSTLVGHDTFTKVKPSAASIDAAKKAGVNNGNPLDAVQQ 
DNA sequence 
 
ATGGCAAGCATGACCGGTGGCCAGCAGATGGGTCGTGATCAGGCAG
GTATTACCGGCACCTGGTATAATCAGCTGGGTAGCACCTTTATTGTTA
CCGCAGGCGCAGATGGTGCACTGACCGGTACGTATGAAAGCGCAGT
TGGTAATGCAGAAAGCCGTTATGTTCTGACAGGTCGTTATGATAGCG
CACCGGCAACCGATGGTAGCGGCACCGCACTGGGTTGGACCGTTGCA
TGGAAAAATAACTATCGTAATGCACATAGCGCAACCACCTGGTCAGG
TCAGTATGTTGGTGGTGCAGAAGCACGCATTAATACCCAGTGGCTGC
TGACCAGCGGCACCACCAGCCCGCTGAGCGAAGCGCTGACCAAAGC
GAACAGCCCGGCGGAAGCGTATAAAGCGAGCCGCGGCGCGGGCGCA
AATGCCTGGAAAAGCACCCTGGTTGGTCATGATACCTTTACCAAAGT
TAAACCGAGCGCAGCAAGCATTGATGCAGCAAAAAAAGCCGGTGTG
AATAATGGTAATCCGCTGGATGCAGTTCAGCAGTAATAG 
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The OmpA tag was cleaved from the previous OmpA Sav-FPD construct to afford the  Sav-FPD 
construct using the reported procedure.
34 
 
The sequences from the four mutants (selected for large scale expression and purification) were 
amplified by PCR (forward primer: 5’-GGG AAT TCC ATA TGG CAA GCA TGA CCG GTG GC, 
reverse primer: 5’-GTT AGC AGC CGG ATC TCA GTG, conditions see Table 4). 
Table 4. PCR conditions for DNA amplification 
 
1x 
MasterMix 
Final concentration 
Sterilized H2O 21 µL  
5x Q5 reaction buffer 12 µL  
5*GC enhancer 12 uL  
dNTPs (10 mM) 1.2 µL 0.2 mM 
Forward Primer (10 µM) 6 µL 1 µM 
Reverse Primer (10 µM) 6 µL 1 µM 
Plasmid prep template (20 ng/µL) 1.5 µL 0.5 ng/µL 
Q5 Hot Start (2 U/µL) 0.3 µL  
total 60 uL  
 
The amplified DNA was digested (NdeI and BamHI restriction enzymes) and ligated into the empty 
pET30 vector (New England BioLabs® T4-DNA Ligase, room temperature, 3 h, 10-fold molar ecess 
of inserts compared to the vector). The ligated products (3 µL) were transformed to TOP10(DE3) 
competent E. coli cells and the suspension was plated onto LB-argar plate (containing kanamycin 50 
µg/mL) at 37 °C overnight. The rest of the ligated product solutions were freezen at -20 °C. Colonies 
were picked for overnight culture (LB medium, 37 °C). The cells were harvested and the plasmids 
were isolated and sequenced. The plasmids (1 µL) with the correct Sav-FPD sequence were 
transformed to BL21(DE3) competent cells and the suspensions were plated on LB-argar plate with 
kanamycin overnight at 37 °C. A single colony was picked for an overnight culture (5 mL LB medium 
in falcon tube) and, the next day glycerol stocks were prepared and kept at -80 °C. 
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Large scale expression in 3 L conical flasks using autoinduction medium 
An autoinduction medium was prepared according to the reported protocol.
21
 (Table 5) For each 
mutant, the cytoplamsic expression was performed in triplicate. 
Table 5. Autoinduction medium for cytoplasmic Sav expression 
 amount for 1 L solution in 3 L elenmyer flask 
tryptone 10 g 
yeast extract 5 g 
20 · ZYP salts 50 mL 
20 · ZYP sugars 50 mL 
MgSO4 (200 mM) 10 mL 
kanamycin (50 mg/mL) 1 mL 
dd H2O 890 mL 
 
The precultures (1 mL) was inoculated to the autoinduction medium (1 L). This main culture was 
incubated at 30 °C, 180 rpm for 24 h. The final OD600 reached to 8-10. The proteins expressed as 
inclusion bodies. 
The cells were harvested by centrifugation (9500 rpm, 10 min, 4 °C) and the supernatant was 
discarded. After freezing at -20 °C overnight, the cell pellets were thawed and treated with lysis buffer 
(150 mL, tris-HCl 20 mM, pH 7.4, lysozyme 1 mg/mL, DNase I 0.1 mg/mL). The suspensions were 
shaken at room temperature for 3 h, frozen 2 h and thawed at rt. The cell lysates were dialysed 
dialysed in guanidium hydrochloride solution (6 M, pH 1.5) overnight at 4 °C. Then, the lysates were 
transfered into refolding buffer (1.5 L, MES 50 mM, pH = 6.0 NaCl 9.6 mM, KCl 0.4 mM, MgCl2 2 
mM, CaCl2 2 mM, arginine 0.5 M and 0.05% polyethlene glycol 3.400) and gently stirred for 4 h at 
4 °C. The resulting solutions were dialysed in an iminobiotin binding buffer (500 mM NaCl, 50 mM 
NaHCO3, pH = 9.8) overnight at 4 °C. Finally, the cell lysates were centrifuged (10000 rpm, 2 h, 4 °C) 
and the supernatant was filtered and purified by AKTA prime. The eluted Sav fractions were collected, 
neutralised with aqueous NaOH to pH 7 and dialyzed in MQ H2O (3 × 24 h). The clear solutions were 
frozen and lyophilized. 
OD600 4/mL cells from the main culture were transferred to Eppendorf tubes, lysed and both soluble 
and insoluble fractions were analyzed by SDS-PAGE. (Figure 2) 
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Figure 2. Overexpressed Sav-FPD mutants in the cytoplasm were visualised using B4F in the 
insoluble fraction under UV-light, revealing the biotin-binding activity of the inclusion bodies. 
The mass of the purified Sav-FPD mutants were determined by ESI/micrOTOF mass spectroscopy. 
(Table 6) 
Table 6 calculated mass values and the measured mass for Sav-FPD mutants 
 Calculated mass of 
the monomer (Da) 
Measured mass (Da) 
Sav-FPD 18654.40 18654.56 
Sav-FPD S112V-K121A 18609.35 18609.46 
Sav-FPD(K9L-N11P) 
S112V-K121A 
18577.35 18577.45 
Sav-FPD(K9I-N11P) 
S112V-K121A 
18577.35 18577.52 
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General procedure of the reduction of imine 4a, 5a, 6a, 7a catalyzed by the artificial 
transfer hydrogenase 
Table 6. Substrate scope for ATHase using mutants identified from self-immolative substrate 1 
 
a 
The conversions and ee were determined either by HPLC (substrates 4a, 5a, 6a) or GC (for 7a). 
Positive ee refers to an excess in favor of the (R)-amine. Negative ee refers to an excess if favour of 
the (S)-amine.  
 
A series of stock solutions were prepared first: [Cp*Ir(biot-p-L)Cl] catalyst (200 µM in MQ water), 
streptavidin stock (400 M biotin binding sites in MQ water), imine substrates 4a, 5a, 6a, 7a stock 
(400 mM in DMSO), quinolinium 1 (40 mM in DMSO) and MOPS buffer (0.8 M, formate 6 M, pH 
7.0). 
In a small glass reaction vial, a MOPS buffer stock solution (100 L), the protein stock solution (10 
L), catalyst stock solution (10 L) and MQ water (75 µL) were added and incubated at 25 °C for 10 
min. Then, the imine substrate or quinolinium substrate stock solution (5 μL) was added, and the 
reaction mixture (200 µL in total) was shaked in a ThermoMixer at 25 °C for 24 h. 
Upon completion of the reaction, the mixture was treated with aq. NaOH (100 μL, 10 M) and 
extracted with ethyl acetate (1 × 1 mL). The mixture was thoroughly mixed, and the organic phase was 
transferred to an Eppendorf tube, dried with Na2SO4 and centrifuged at 14’000 rpm for 10 minutes. 
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The supernatant (700 μL) was transferred in an HPLC vial and subjected to HPLC or GC analysis to 
determine the conversion and ee. 
Transfer hydrogenation catalysis of imines 4a,
34
 5a,
45 
6a,
20
 7a
34
 were analyzed using the reported 
methods. 
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NMR Spectra: 
1
H NMR (400 MHz, DMSO-d6)  
 
 
13
C NMR (100 Hz, DMSO-d6)  
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1
H NMR (500 MHz, DMSO-d6)  
 
 
13
C NMR (125 Hz, DMSO-d6) 
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ESI/micrOTOF mass spectrum of the purified Sav-FPD mutants 
 
 
 
 
Sav-FPD 
Sav-FPD S112V-K121A 
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Sav-FPD(K9L-N11P) S112V-K121A 
Sav-FPD(K9I-N11P) S112V-K121A 
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Chapter 5 │ Conclusion and outlook 
Three ArMs, combining complexes of either Ru, Rh or Ir with the protein scaffolds human carbonic 
anhydrase II or streptavidin were explored. Good activities of these ArMs were observed for non-
natural reactions: namely ring closing metathesis, carbene transfer reactions and transfer 
hydrogenation.  
The study presented in chapter 2 demonstrates robust activity of a ruthenium-based artificial 
metathesase using the human carbonic anhydrase II scaffold with low catalyst concentration and 
physiological conditions. The hCA II mutants displayed binding affinities for the Ru-complex in the 
nanomolar range. This ArM would be suitable for further applications in cascade reactions e.g. for the 
synthesis of cyclic alkenes, in which natural enzymes involved in the cascade require a pH-neutral 
environment. So far no protein-acceleration has been observed for this system. This might be 
overcome by further substrate and scaffold engineering efforts. Directed evolution of hCA II for the 
task at hand would be an attractive way to search the sequence landscape for improved activity. In 
particular the combination with computational design for informed choices on randomization sites 
should be considered. 
Chapter 3 reports on the successful synthesis of various biotinylated dirhodium complexes and the 
good activity of these complexes embedded in streptavidin mutants. The dirhodium ArMs catalysed 
intermolecular cyclopropanation and C-H insertion with high efficiency under neutral conditions. The 
ArMs assembled in the periplasm of E. coli cells showed good activity for cyclopropanation. A 
modelled structure of a dirhodium complex within Sav suggested that the dirhodium metal centers are 
too distant from any amino acid residues from the protein scaffold, thereby providing an rationale why 
no enantioselectivity for the tested cyclopropanation and C-H insertion was observed. To simulate the 
traditional chiral dirhodium complexes carrying bulky carboxylate ligands, additional motifs could be 
added close to the dirhodium center, such as loops inserted at different locations around the putative 
active site.  
Chapter 4 summarizes the implementation of a streamlined screening protocol for the evaluation of 
loop mutants of an artificial transfer hydrogenase. The identified, purified loop mutants outperformed 
Sav WT in combination with the iridium-cofactor in the transfer hydrogenation of imines up to 
fivefold in terms of turnover numbers, although the enantioselectivity was not improved significantly. 
A self-immolation strategy was successfully used to analyse transfer hydrogenation catalysis results by 
fluorescence, greatly increasing the screening thoughput. 
Directed evolution is a powerful method to engineer enzymes for a particular application. Beneficial 
mutations are accumulated over multiple generations and enhance the enzymes’ performance. As the 
situation is even more complicated for the engineering of ArMs by directed evolution, some issues 
should be considered before a project of directed evolution of artificial metalloenzymes is undertaken. 
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(1) It would be advantageous if protein concentrations could be kept equal among members of a 
mutant library to not only match catalyst concentration, but also cofactor/host-protein ratio. (2) A 
suitable reaction and reaction conditions have to be identified which are sensitive to subtle changes of 
the catalyst structure. In a typical protocol mutations of residues near the active site would be targeted 
first, their choice often inspired by modelling studies.  (3) It should be considered whether the system 
is indeed suitable for directed evolution protocols. E.g. if the catalytic center is projected outside of the 
protein scaffold, as hypothesized for the dirhodium constructs presented in chapter 3, high-throughput 
screening efforts without substantial protein engineering (e.g. the introduction of additional loops) is 
unlikely to yield improved mutants.  
 
 
